



## Review article

## Redox control of cancer cell destruction

Csaba Hegedűs<sup>a,1</sup>, Katalin Kovács<sup>b,1</sup>, Zsuzsanna Polgár<sup>a,1</sup>, Zsolt Regdon<sup>a,1</sup>, Éva Szabó<sup>c</sup>, Agnieszka Robaszekiewicz<sup>d</sup>, Henry Jay Forman<sup>e</sup>, Anna Martner<sup>f</sup>, László Virág<sup>a,b,\*</sup>

<sup>a</sup> Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

<sup>b</sup> MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary

<sup>c</sup> Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

<sup>d</sup> Department of General Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland

<sup>e</sup> Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA

<sup>f</sup> TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden



## ARTICLE INFO

## Keywords:

Cancer  
Redox regulation  
Natural killer cells  
Cytotoxic lymphocytes  
Chemotherapeutics  
Free radicals  
Antioxidants

## ABSTRACT

Redox regulation has been proposed to control various aspects of carcinogenesis, cancer cell growth, metabolism, migration, invasion, metastasis and cancer vascularization. As cancer has many faces, the role of redox control in different cancers and in the numerous cancer-related processes often point in different directions. In this review, we focus on the redox control mechanisms of tumor cell destruction. The review covers the tumor-intrinsic role of oxidants derived from the reduction of oxygen and nitrogen in the control of tumor cell proliferation as well as the roles of oxidants and antioxidant systems in cancer cell death caused by traditional anticancer weapons (chemotherapeutic agents, radiotherapy, photodynamic therapy). Emphasis is also put on the role of oxidants and redox status in the outcome following interactions between cancer cells, cytotoxic lymphocytes and tumor infiltrating macrophages.

## 1. Introduction

Cancer represents the toughest challenge for modern medicine and is responsible for approximately 9 million deaths worldwide with more than 14 million new cases reported each year [1,2]. Therefore, understanding formation and spreading of cancer as well as mechanisms for

developing therapy resistance are of crucial importance for the development of new effective treatments.

Most aspects of cancer biology display some degree of redox regulation. Carcinogenesis, cancer cell proliferation, migration, invasion, metastasis and vascularization all appear to be under redox control. Moreover, inflammatory cells in the tumor microenvironment may

**Abbreviations:** ABC transporters, ATP-binding cassette transporters; ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cancer cell phagocytosis; AML, acute myeloid leukemia; APE1, apurinic/apyrimidinic endonuclease 1; ASK-1, apoptosis signal-regulated kinase 1; CAF, cancer-associated fibroblast; CAR-T cells, Chimeric Antigen Receptor T-Cell; CLL, chronic lymphoid leukemia; CLS, cytotoxic lymphocytes; cPLA, cytosolic phospholipase A; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DAMP, damage-associated molecular pattern; DCFH 2', 7'-dichlorodihydrofluorescein; DCs, dendritic cells; DDB, Biphenyl Dimethyl Dicarboxylate; DDR, DNA damage response; Dox, doxorubicin; DUOX, nicotinamide adenine dinucleotide phosphate (NADPH) dual oxidase; EGF, Epidermal growth factor; EGFR, Epidermal growth factor receptor; EMT, epithelial mesenchymal transition; eNOS, Endothelial NOS; ER, Endoplasmic reticulum; ERK, extracellular signal-regulated kinase; ETO, etoposide; FAS, first apoptosis signal; GFR, growth factor receptor; GM-CSF, Granulocyte-macrophage colony-stimulating factor; GPx, glutathione peroxidase; GSH, glutathione; GST, Glutathione transferase; HDC, histamine dihydrochloride; Her/hER, human Estrogen Receptor; HIF-1  $\alpha$ , hypoxia inducible factor 1 $\alpha$ ; HMGB1, high mobility group box 1; IL-2, Interleukin-2; ILT, immunoglobulin like transcripts; ImC, immature myeloid cell; HMGB1, high mobility group box 1; HMGB1, high mobility group box 1; KIR, killer immunoglobulin-like receptor; LOOH, lipid hydroperoxide; LPO, lipid peroxidation products; LPS, Lipopolysaccharide; MAP, mitogen-activated protein; MAPKKK, mitogen-activated protein kinase kinase kinase; M-CSF, macrophage colony-stimulating factor; MDR, multiple drug resistance; MDSC, myeloid derived suppressor cell; MHC-I, major histocompatibility complex type I; MnTBAP, Mn(III)tetrakis (4-benzoic acid) porphyrin; NAC, N-acetylcysteine; M $\Phi$ , macrophage; NADPH, nicotinamide adenine dinucleotide phosphate; NCR, natural cytotoxicity receptor; NF $\kappa$ B, nuclear factor kappa-light-chain-enhancer of activated B cells; NK, Natural Killer cells; nNOS, Neuronal NOS; NO, nitric oxide; NOS, nitric oxide synthase; NOX, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase; NQO1, NAD(P)H:quinone oxidoreductase 1; Nrf2, nuclear factor erythroid 2-related factor 2; NSCLC, Non-Small Cell Lung Cancer; ONOO-, peroxynitrite; PARP1, Poly (ADP-ribose) polymerase 1; PBMC, Peripheral blood mononuclear cell; PD1, Programmed cell death protein 1; PDGF, Platelet-derived growth factor; PD-L1, Programmed death-ligand 1; PDT, Photodynamic therapy; PEDF, pigment epithelium derived factor; PGE2, Prostaglandin E2; PhGPx, phospholipid hydroperoxide glutathione peroxidase; PI3K, Phosphatidylinositol 3-kinase; PEDF, pigment epithelium derived factor; PGE2, Prostaglandin E2; PhGPx, phospholipid hydroperoxide glutathione peroxidase; PI3K, Phosphatidylinositol 3-kinase; PK, pyruvate kinase; SOD, superoxide dismutase; TAMs, tumor-associated macrophages; TCR, T cell receptor; TGF $\beta$ , Transforming growth factor beta; TLR, Toll-like receptor; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; TrxR1, thioredoxin reductase 1; VEGF, Vascular endothelial growth factor

\* Corresponding author at: Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Egyetem tér 1, H-4032 Debrecen, Hungary.

E-mail address: [lvirag@med.unideb.hu](mailto:lvirag@med.unideb.hu) (L. Virág).

<sup>1</sup> These authors contributed equally to the work.

<https://doi.org/10.1016/j.redox.2018.01.015>

Received 16 December 2017; Received in revised form 25 January 2018; Accepted 31 January 2018

Available online 03 February 2018

2213-2317/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

produce superoxide, hydrogen peroxide and nitric oxide which impacts on both the cancer cells and the neighboring regulatory or effector immune cells. Many of these aspects of cancer biology have been extensively reviewed and therefore this paper focuses on the redox control of cancer cell destruction. Killing the cancer cells is the ultimate goal of both traditional therapies such as chemotherapy and ionizing radiation and of biological therapies such as checkpoint inhibitors (e.g. anti-PD1 and anti-CTLA-4 antibodies) [3], anticancer antibodies (e.g. against EGFR or Her antigens) [4,5] and adoptive cell therapies (e.g. with NK cells, cytotoxic T lymphocytes, T cells expressing chimeric antigen receptors; CAR-T cells) [6,7]. Other targeted treatment modalities; e.g., inhibitors of tumor vascularization (VEGF pathway inhibitors), tyrosine kinase inhibitors, hormone therapy indirectly also result in tumor cell death [8].

Redox control is known to affect the biology of tumors at multiple levels:

- a) Redox signaling has a great impact on tumor cell proliferation. Signals through growth factor receptors (GFR) as well as integrins stimulate production of superoxide ( $O_2^{\cdot-}$ ), which dismutates to hydrogen peroxide ( $H_2O_2$ ) or production of  $H_2O_2$ , directly. These oxidants are produced by NADPH oxidases (NOXs) that are activated via largely overlapping pathways [9]. Stimulation of GFRs (e.g. epidermal GFR, insulin-like GFR, transforming GFR beta, platelet-derived GFR) by their specific growth hormones or ligation of integrins by extracellular matrix components trigger the Ras-Raf-Erk and the PI3K-Akt signaling pathways required for proliferation [10,11]. These signaling pathways also converge on NOXs that produce  $O_2^{\cdot-}$  and  $H_2O_2$  (mainly by growth factor receptors). Lipoxigenases, which produce lipid hydroperoxides among their products, are stimulated through integrins. Hydroperoxides produced by these sources stimulate receptor tyrosine kinases and inhibit protein tyrosine phosphatases, thus sensitizing cells to proliferation signals [12]. It should be noted that hydroperoxides and not superoxide, hydroxyl or other oxygen centered species function as a second messenger [13].
- b) Even in non-transformed cells a small amount of oxygen is partially reduced by the mitochondrial electron transport chain resulting in superoxide production. Cancer cells may utilize a Warburg type metabolism; i.e., they rely on glycolysis for energy production even if oxygen is abundant (aerobic glycolysis). It has been proposed that the Warburg phenomenon aims to spare oxygen for the production of  $H_2O_2$  that is used for redox signaling to promote tumor cell proliferation [14]. It has also been documented that defects in mitochondrial oxidative metabolism, as observed in cancer cells, may give rise to superoxide, hydrogen peroxide, hydroperoxide production and increased glucose utilization aims to provide reducing equivalents through NADPH and pyruvate necessary for metabolizing hydroperoxides [15,16].
- c) Many cells in a tumor mass undergo cell death due to various factors including insufficient supply of oxygen and nutrients, attack by infiltrating cytotoxic immune cells and anti-cancer treatments (chemotherapy, irradiation and immunotherapy). Cells undergoing apoptotic or necroptotic cell death overproduce  $H_2O_2$  due to disruption of the mitochondrial electron transport system [17].
- d) In relation to the previous point, tumor cells undergo repetitive ischemia-reperfusion cycles due to their irregular blood supply not always on a par with their ever increasing demand for oxygen and nutrients as required for rapid growth.
- e) The relationship between cancer and inflammation is complex. On the one hand, many (but not all) chronic inflammatory conditions predispose to cancer and, on the other hand, the tumor microenvironment is also characterized by varying degree of inflammation [18]. Infiltrating immune cells produce a plethora of cytokines and chemokines in the tumor fueling inflammation accompanied by the production of  $O_2^{\cdot-}$  and hydroperoxides, and species derived from

nitric oxide (NO), including peroxynitrite. NO is produced by nitric oxide synthases [19], one of which (eNOS/NOS3) is constitutive in cells and regulated through calcium and kinase signaling, a second (iNOS/NOS2) is regulated at the level of transcription, and a third (nNOS/NOS1) is both inducible and signaling regulated. NO is a well characterized second messenger that activates guanylate cyclase [20]. Signaling by peroxynitrite is controversial [21]. While  $H_2O_2$ , lipid hydroperoxides and NO are involved in signaling, other species, particularly in the presence of iron freed from proteins, can cause oxidative damage to macromolecules and disrupt cell integrity. The inflammatory tumor environment promotes tumor progression by increasing genetic instability, it stimulates metastasis and may also be involved in therapy resistance [22]. However, extensive cell death in the inflamed tumor environment (especially cell death involving oxidant-based ER stress, which occurs in response to certain therapies) may lead to release of tumor antigens. Uptake of tumor antigens by antigen presenting cells (dendritic cells and macrophages) results in antitumor adaptive immune responses (immunogenic cell death).

## 2. The cancer redox environment

### 2.1. Sources and types of oxidants in tumors

Oxygen and nitrogen centered oxidants, often called by the vague terms reactive oxygen and nitrogen species are formed by many cell types in the tumor microenvironment, including cancer cells, stroma cells, endothelial cells, innate and adaptive immune cells. As described above, the main species produced in tumors, as well as normal tissues, are superoxide, hydrogen peroxide, lipid hydroperoxides, NO and peroxynitrite. In tumors, production of these may be greater [23]. All cells generate  $O_2^{\cdot-}$  and  $H_2O_2$  as by-products of mitochondrial ATP generation in the electron transport chain. In addition,  $O_2^{\cdot-}$  and  $H_2O_2$  are produced in a regulated fashion by the nicotinamide adenine dinucleotide phosphate (NADPH) oxidases known as NOX and by the dual oxidases (DUOX). These families of transmembrane proteins comprise NOX1-5 and DUOX1-2 and their only known function is to produce  $O_2^{\cdot-}$  and  $H_2O_2$ , some by one-electron and some by two-electron reduction of oxygen [8,24–26].

Membrane bound NOXs have been identified as major sources of oxidants in cancer. While NOX1 has been implicated mostly in the regulation of colon cancer cell proliferation, DUOX enzymes have been linked to the control of epithelial mesenchymal transition (EMT), invasiveness in cancer cell lines (DUOX1) and induction of VEGF and HIF-1 $\alpha$  expression in pancreatic cell lines (DUOX2) [27,28]. NOX2 is, as will be discussed in a later section, highly expressed in myeloid cells but may also be expressed at lower levels by other cell types. For example EBV-infected gastric cancer cells have been shown to express enhanced NOX2 levels, which contributes to tumor progression [29] and NOX2-derived radicals have been suggested to contribute to Bim-induced apoptosis in non-small cell lung cancer cell lines [30]. Recently NOX4 attracted increasing attention. NOX4 was found to localize to the perinuclear region, nucleus, endoplasmic reticulum, plasma membrane and also to the mitochondria [31–33]. NOX4 primarily generates  $H_2O_2$  but mutation of a conserved histidine in its third extracytosolic loop (E-loop) can switch the protein to a superoxide generating enzyme [34].

The role of NOX4-derived oxidants in cancer is tumor context and therapeutic modality specific. For example, in renal cancer cells NOX4 has been found to localize to the mitochondrial inner membrane in an ATP bound inactive form [35]. NOX4 was activated upon ATP redistribution from mitochondria which led to metabolic reprogramming (a hallmark of cancer) and resistance to the anticancer drug etoposide. The underlying mechanism involved NOX4 derived oxidants which caused inhibition of acetylation-mediated lysosomal degradation of the “oncogenic” M2 splice variant of pyruvate kinase (PKM2) in etoposide-treated cells. These data identify NOX4 as a novel energetic sensor

within the mitochondria, which serves as a checkpoint to couple mitochondrial energy metabolism to drug resistance in cancer cells [35]. Similar tumor promoting role of NOX4 has been reported in breast and ovarian cancer. These tumors overexpress NOX4 resulting in H<sub>2</sub>O<sub>2</sub>-dependent senescence, increased tumorigenicity and etoposide resistance [33]. The tumor promoting, prosurvival and antiapoptotic role of NOX4 which is mediated by Akt kinase activation as demonstrated in pancreas adenocarcinoma cells [36,37] may also contribute to therapy resistance. In contrast, in head and neck cancer cells the EGFR tyrosine kinase inhibitor Erlotinib caused upregulation of NOX4 and down-regulation of NOX1,2,5. H<sub>2</sub>O<sub>2</sub> produced by NOX4 was essential for Erlotinib-induced cancer cell death [38].

Another well examined enzyme that generates O<sub>2</sub><sup>•-</sup> and H<sub>2</sub>O<sub>2</sub> is xanthine oxidase, which catalyzes the oxidation of hypoxanthine to xanthine and ultimately to uric acid [39]. There are many other oxidoreductases in cells that can produce O<sub>2</sub><sup>•-</sup> and H<sub>2</sub>O<sub>2</sub>, but many are confined to peroxisomes where the catalase concentration is very high. As mentioned above, nitric oxide is produced by nitric oxide synthase (NOS) enzymes with NOS2 (inducible NOS) and NOS3 (endothelial NOS) being the most important sources in tumors. NO can react with superoxide to form peroxynitrite. The presence of this short-lived and highly reactive oxidant is evidenced by detection of its footprints nitrotyrosine and 8-nitroguanine in proteins and DNA/RNA of tumors, respectively [40]. The tumor infiltrating myeloid cells, such as myeloid derived suppressor cells (MDSCs) and macrophages often constitute the major source of oxidizing species generated via the enzymatic systems. However, in different tumors the dominant source, the amount of oxidants produced and the role of these radicals for cancer progression or destruction may vary. Also, the applied anti-cancer treatments and antioxidant enzyme expression in the tumor microenvironment may affect redox status and outcome.

## 2.2. Redox sensors

While oxidants have been viewed for decades as cell damaging agents, hydroperoxides and nitric oxide are now widely recognized as unique signaling molecules. Their signaling role is mediated mostly by enzymatic oxidation of certain cysteine residues by H<sub>2</sub>O<sub>2</sub> to either disulfides or mixed disulfides with glutathione resulting in altered protein structure and functional state [41]. These modifications are reversed by specialized reducing proteins glutaredoxins and protein disulfide reductases. For example in non-oxidatively stressed cells, one of the MAPKKK enzymes named apoptosis signal-regulated kinase 1 (ASK-1) is kept inactive by association with reduced thioredoxin. Upon formation of a disulfide bond in thioredoxin via peroxiredoxin-catalyzed oxidation of two critical cysteines by H<sub>2</sub>O<sub>2</sub>, the oxidized thioredoxin dissociates from ASK-1 permitting its oligomerization and activation [42]. H<sub>2</sub>O<sub>2</sub> may also prolong MAP kinase signals by directly inactivating MAP kinase phosphatases via cysteine oxidation, again most likely through an enzyme catalyzed process [43]. Similarly, in growth factor signaling, oxidation of the phosphatase PTEN permits peptide growth factor (e.g. PDGF or EGF)-induced H<sub>2</sub>O<sub>2</sub> production to mediate sustained proliferation signals [44].

Induction of certain cellular antioxidant enzyme systems also occurs via redox signaling mechanisms. The key regulator in this pathway is Nrf2 (nuclear factor erythroid 2-related factor 2) which is targeted for degradation via association with KEAP-1 (kelch-like ECH-associated protein 1). Upon oxidation of key cysteines in KEAP-1, it no longer can facilitate the ubiquitination of Nrf2 which in turn allows newly synthesized Nrf2 to translocate to the nucleus and bind to EpRE (also known by the misnomer antioxidant response element, ARE) in the promoters of antioxidant genes such as glutathione S-transferase, glutathione peroxidase subunits of glutamate-cysteine ligase and NADPH-quinone oxidoreductase 1 to induce their expression [45].

## 2.3. Cellular antioxidant systems

Tissue damage caused by excessive production of oxidants is prevented by antioxidant enzymes. In mammals, the former class include superoxide dismutases (SOD1 and SOD2), catalase, the glutathione peroxidases (GPx 1–8) and the peroxiredoxins (Prdx 1–6) [46]. SODs convert superoxide to H<sub>2</sub>O<sub>2</sub> (and O<sub>2</sub>) while catalase, the glutathione peroxidases and peroxiredoxins reduce H<sub>2</sub>O<sub>2</sub> to H<sub>2</sub>O. GPxs and Prdx6 use glutathione as the reducing substrate, Prdxs 1–5 use reduced thioredoxin, and catalase dismutates H<sub>2</sub>O<sub>2</sub> to H<sub>2</sub>O and O<sub>2</sub>.

While all antioxidant enzymes have been linked to various aspects of cancer biology, SOD2 deserves special attention. On the one hand, many cancers downregulate SOD2 expression while, on the other hand, SOD2 overexpression has been shown to suppress tumorigenesis and cancer cell proliferation with hydrogen peroxide and nitric oxide being likely effectors [47]. In mouse embryonic fibroblasts the tumor suppressive effect of SIRT3 has been shown to be mediated by SOD2 overexpression pointing towards a role of mitochondrial superoxide in cell transformation in a single oncogene expression setting [48]. Mitochondrial superoxide also plays a central role in the anticancer effect of pharmacological ascorbate [49]. Ascorbate selectively induces mobilization of iron from Fe-S clusters and thus increases labile iron pool. Increased steady state levels of superoxide and H<sub>2</sub>O<sub>2</sub> were commonly observed in many types of cancer and have also been implicated in the disruption of homeostatic iron metabolism; a finding also observed in tumor cell killing by pharmacological ascorbate. Under this condition SOD2 increased resistance of tumor cells to ascorbate-mediated cell killing. In different therapeutic settings, where the effects of the DNA alkylating agent and glutathione reductase inhibitor BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) was investigated, higher SOD2 activity was accompanied by higher toxicity. Combination of SOD2-mediated H<sub>2</sub>O<sub>2</sub> production and impaired H<sub>2</sub>O<sub>2</sub> removal due to glutathione peroxidase inhibition appeared to be a key factor in this toxicity [47].

In MCF7 cells superoxide was found to stabilize hypoxia inducible factor-1 $\alpha$  (HIF1 $\alpha$ ), a positive regulator of transcription of genes responsible for angiogenesis, proliferation, survival and metastasis [50] and this pathway was inhibited by SOD2 overexpression.

There are thousands of compounds that have antioxidant chemistry *in vitro* and appear to have some antioxidant effect *in vivo*. Scavenging of oxidants is actually a competition between organic molecules, including both small metabolites, vitamins and macromolecules, because the rate constants for these reactions are usually very close to each other. For a molecule to be effective as oxidant scavenger *in vivo*, it would need to outcompete all other molecules [51]. This simply does not happen inside of cells except for vitamin E, which is concentrated in membranes where it reacts with hydroperoxyl radicals. Scavenging of superoxide, hydrogen peroxide and other hydroperoxides is carried out efficiently by enzyme catalyzed reactions with rate constants that are 100,000 times faster than for the non-enzymatic reactions. Thus, among the naturally occurring metabolites and vitamins, with the exception of vitamin E, there is no physiologically meaningful scavenging by non-enzymatic reactions. The only other significant antioxidant effect of small molecules are chelators that tie up iron so that it cannot catalyze the production of hydroxyl radical, and inhibitors of NOX, NOS and other oxidoreductases, as inhibitors of production rather than scavengers of oxidants; e.g., NOX2-inhibitors [52], NOS inhibitors, xanthine oxidase inhibitors) or induce antioxidant defenses (e.g. Nrf-2 activators) [53]. In cells, the dominant cellular “antioxidant” molecule is glutathione, which is used by GPxs and Prdx6 rather than as a direct scavenger of any oxidant.

## 3. Oxidative stress induced by conventional anticancer therapy (ionizing radiation, chemotherapeutic agents, PDT)

Conventional anticancer therapy includes the use of chemotherapeutic agents, radiotherapy or photodynamic therapy. Hydroxyl

radical and singlet oxygen production are common mechanisms of many therapeutic approaches for cancers (photodynamic therapy, radiotherapy, doxorubicin) and is also responsible for many of their side effects. These approaches involve the production of species that are associated with damage rather than redox signaling. Of course, damage itself is recognized by cells and stimulates signaling that may include redox signaling.

### 3.1. Radiotherapy

Radiotherapy is given for eliminating tumor cells (curative treatment) or for relieving the symptoms of patients (palliative treatment). It can be applied internally (with a radioactive material) or externally (high-energy x-rays at the affected area). Radiotherapy utilizes high-energy rays and its main cellular target is DNA [54]. Single and double strand breaks, crosslinks between DNA strands and chromosomal proteins are induced. While electromagnetic radiation ionizes indirectly through inducing the formation of hydroxyl radicals, heavy particles such as alpha particles [55] and carbon ions [56] can cause DNA damage directly, hence with higher biological effectiveness. Alpha particles have relatively short range ( $\leq 100 \mu\text{m}$ ) resulting in partial tumor irradiation and limited killing.  $^{223}\text{Radium}$  and many other newly developed alpha emitters may offer the potential for targeted therapy via conjugation with specific antibodies or targeted nanoparticles [57]. Carbon ion has quite favorable physical and biological properties for cancer therapy [56]. It provides a sufficient radiation dose to the tumor, while causing acceptable damage in the surrounding normal tissues. Adenocarcinoma, adenoid cystic carcinoma, malignant melanoma, hepatoma, and bone/soft tissue sarcoma respond favorably to carbon ion radiotherapy. Radiation induces tumor cell death or permanent cell cycle arrest [58]. It destroys cancer cells, but may also damage normal cells [59]. However, compared to non-transformed cells, DNA repair in cancer cells is often defective making them more vulnerable to radiotherapy.

### 3.2. Chemotherapy

Classical chemotherapeutics can be classified as alkylating agents, antimetabolites, topoisomerase inhibitors and anti-microtubule agents.

#### 3.2.1. Alkylating agents

By definition, alkylating agents are compounds capable of replacing a hydrogen atom in another molecule by an alkyl radical. Alkylating agents (cyclophosphamide, ifosfamide, chlorambucil) can be toxic, mutagenic, carcinogenic or teratogenic at different doses. They decrease the rate of cell division, and may cause breakage and other abnormalities of chromosomes [60]. Alkylating agents interfere with DNA replication by crosslinking DNA strands, causing DNA strand breaks and abnormal base pairing. They tend to be more effective against rapidly dividing cells. In particular, impairment of replicative fidelity of DNA during the S-phase could contribute to some of the mitotic and chromosomal effects, as well as to their carcinogenic and teratogenic potencies [60]. The nitrosoureas are a subgroup of the alkylating agents interfering with DNA replication and repair. Platinum-containing compounds include agents such as Cisplatin, Carboplatin and Oxaliplatin and their cytotoxic properties also extend to alteration of the cell membrane transport systems and suppression of mitochondrial function [61]. Cisplatin is used to treat various types of cancers such as testicular, lung, and ovarian cancers. This drug exhibits multiorgan toxicity with redox imbalance as a possible mechanism [62,63].

#### 3.2.2. Topoisomerase inhibitors

Topoisomerases I and II can relax DNA supercoiling (e.g. during replication or transcription) by breaking and rejoining the backbone of DNA strands. They also play a significant role in fixing DNA damage that occurs as a result of exposure to harmful chemicals or UV rays.

Inhibitors of topoisomerase I (e.g. topotecan, camptothecin) and topoisomerase II (e.g. etoposide, doxorubicin) work by binding to the topoisomerase enzymes and blocking DNA religation after strand cleavage [64,65].

#### 3.2.3. Anti-microtubule agents

Tubulin proteins form spindle fibers (also called microtubules) which is essential for cell division. Vinca alkaloids (Vinblastine, Vincristine) bind to tubulin, inhibiting cytoskeletal dynamics [66].

#### 3.2.4. Antimetabolites

Antimetabolites (methotrexate, 5-fluorouracil and cytosine arabinoside) act as analogs of nucleotides interfering with DNA and RNA synthesis. Most of these agents are specific for S phase, therefore they are mostly effective against fast-growing tumors.

#### 3.2.5. Epigenetic reprogrammers

In the pathogenesis of various hematological malignancies (e.g. myelodysplastic syndrome and different forms of leukemias) a critical event is the silencing of tumor suppressor genes via hypermethylation of their promoters. The cytosine analogs 5-azacytidine and 5-aza-2'-deoxycytidine (also known as decitabine) can inactivate DNA methyltransferase [67] and can thus restore the activity of suppressed genes.

### 3.3. Photodynamic therapy (PDT)

Photodynamic therapy (PDT) utilizes the combination of light and photosensitizing drugs [68]. When exposed to light with a specific wavelength, photosensitizers (e.g. porfimer sodium) produce singlet oxygen. Singlet oxygen is a dienophile that attacks histidine in proteins and bases in DNA among other targets. The wavelength determines how far the light can travel into the body. Generally, the light needed to activate most photosensitizers cannot pass through more than 1 cm. The photosensitizing agent (given systemically) accumulate in the tumor cells. The tumor is exposed to the light 24–72 h after the injection, when most of the drug is eliminated from the normal cells. PDT can act in two additional ways as well: it can activate the immune system to kill tumors or it can inhibit the metabolism of the tumors by damaging their blood vessels. PDT is a local treatment (typically on or just under the skin) and generally cannot be used to treat metastasized cancer, but can be combined with other therapies. As laser light can be directed through optical fibers, it can deliver light to the inside of the body, so that esophagus or lung cancers can also be treated. Singlet oxygen reacts with the polyunsaturated fatty acids of the membranes, producing lipid hydroperoxides (LOOHs) [69]. The effectiveness of PDT depends on various factors. The addition of ascorbate and ferrous iron increase the cytotoxic effect of PDT by further augmenting lipid peroxidation and the conversion of LOOHs to more cytotoxic species [69]. It was reported [70] that singlet oxygen generated by photodynamic treatment can inactivate cellular antioxidant enzymes (catalase, SOD1 and SOD2) in nucleated mammalian cells, which can contribute to cytotoxicity. Elevated phospholipid hydroperoxide glutathione peroxidase (PhGPx) enzyme activity, on the other hand, could contribute to the resistance of tumor cells to PDT [71].

### 3.4. Oxidative stress induced by conventional cancer therapy

In radiotherapy and PDT singlet oxygen production is in the very heart of their mechanism of action (see above). The anthracycline **doxorubicin** (Dox) may generate oxidants by more than one mechanism [72,73]. Dox itself can be converted by mitochondrial reductases to anthracycline semiquinone free radicals. Under aerobic conditions, they are able to reduce molecular oxygen to  $\text{O}_2^-$  and  $\text{H}_2\text{O}_2$  [74]. Reactions between iron and Dox can also generate hydroxyl radical through the Fenton reaction. A dose-dependent cardiotoxicity is a



well-known side effect of Dox therapy and is a major limitation to its use. Cardiotoxicity is partly caused by doxorubicin-dependent free radical formation, lipid peroxidation and mitochondrial dysfunction [75]. The alkylating agent **cyclophosphamide** is widely used to treat ovarian, breast, and hematological cancers. An adverse effect of cyclophosphamide chemotherapy is a reproductive failure and premature ovarian insufficiency. The mechanism that causes the above-mentioned symptoms includes the markedly increased production of oxidants [76]. The alkylating agent **cisplatin** is a platinum complex that has been shown to increase oxidative stress by increasing the levels of superoxide anion, hydrogen peroxide and hydroxyl radical [62,63]. The topoisomerase II inhibitor **etoposide** (ETO) is a commonly used chemotherapeutic drug the application of which is limited by its side effects with the kidney being the most sensitive target where ETO induces oxidant generation resulting in necrotic cell death [64]. **Beta lapachone** represents a novel anticancer prodrug activated by NAD(P)H:quinone oxidoreductase 1 (NQO1). NQO1 is overexpressed in many cancers, making this enzyme ideally suited for intracellular drug activation [77]. Bioactivation of  $\beta$ -lapachone by NQO1 involves a futile redox cycle resulting in the release of high amounts of superoxide and hydrogen peroxide. Oxidant-mediated DNA strand breaks are known to trigger overactivation of the DNA break sensor enzyme PARP1 [78] resulting in NAD/ATP depletion and consequent necrotic cell death [79–82] and the same sequence of events has been observed in  $\beta$ -lapachone-treated cancer cells [83]. Combination of  $\beta$ -lapachone with radiotherapy [84] or with PARP inhibitors has also been reported to be a synergistic chemotherapeutic modality [85]. In the latter combination, high amount of oxidants triggered by  $\beta$ -lapachone caused severe DNA lesions, which were not repaired due to PARP inhibition. PARP inhibition also converted  $\beta$ -lapachone-induced necrotic cell death to apoptosis.

Various chemotherapeutic modalities utilize oxidants, which contribute, at least in part, to the elimination of tumors (Table 1). In other cases, oxidant formation is responsible for the side effects of the treatments. Sharma et al. detected significantly elevated plasma lipid peroxide and lower antioxidant levels in patients with cervical cancer, compared to healthy controls [86]. After cisplatin or bleomycin treatment, which was combined with fluorouracil, a relationship was found between the change in lipid peroxide and antioxidant levels and the response to the treatment. The therapeutic response could be predicted by the initial antioxidant levels, and the extent of their change during the therapy. Also in the case of advanced non-small cell lung cancer patients, elevated levels of lipid peroxides and NO was detected (compared to controls) [87,88]. After cisplatin-based combination chemotherapy, even higher indices of oxidative stress were measured. Elevation was more evident in higher stage than lower stage patients.

Selenium compounds and other small molecules, some mislabeled as antioxidants, have anti-cancer effects. Selenium compounds (e.g. sodium selenite) induce apoptosis in cancer cells, which is mediated by H<sub>2</sub>O<sub>2</sub> via a mitochondrial-dependent pathway [89]. In drug-sensitive human tumor cells and in adult male Wistar rats, protective effect of specific antioxidant agents (sodium selenite, selenomethionine) was detected during cytotoxic action of doxorubicin in vitro. In contrast, there was no protective effect in drug-resistant sublines of these tumor cells during action of doxorubicin and cisplatin [90]. In the rat model of squamous cell carcinoma, curcumin not only decreased the survival and the proliferation of the tumors, but sensitized tumors by targeting pSTAT3 and Nrf2 pathways [91]. Curcumin protected against the toxic effect of cisplatin.

Glutathione transferases (GSTs) and TrxR1 are often overexpressed in tumors and frequently correlated with bad prognosis and resistance against a number of different anticancer drugs. Prodrugs have been developed that are derivatives of existing anticancer drugs (etoposide, doxorubicin) incorporating a sulfonamide moiety. With these drugs GSH levels can be decreased and also the redox regulatory enzyme thioredoxin reductase 1 (TrxR1) can be inhibited [92]. Synthetic nitric

oxide releasing compounds (e.g. Bifendate (DDB) nitric oxide) are also effective tools, even in MDR tumors as they are not affected by ABC transporters. Their effect is based on releasing high amounts of NO in tumor cells, which causes mitochondrial tyrosine nitration and apoptosis. Downregulation of HIF1 $\alpha$ , PKB (AKT), ERK and activation of NF $\kappa$ B was detected in MDR cells [93]. Huang et al. [94] could selectively target cancer cells with estrogen derivatives, which caused apoptosis in human leukemia cells but not normal lymphocytes. The selectivity was found to be based on the inhibition of SOD1 and SOD2. Overproduction of catalase (or application of its analogs) combined with chemotherapeutic drugs was also found to suppress the proliferation and aggressiveness of lung cancer [95].

Human AP endonuclease is an essential enzyme of base excision repair, but also acts as a redox signaling factor. Silencing of APE1/Ref1 in A2780 and CP70 cell lines resulted in increased apoptosis [96]. Il'yasova et al. [97] found at least two different types of redox homeostatic mechanisms balancing oxidative stress in humans, which predispose to drug resistance and toxicities during doxorubicin and cyclophosphamide chemotherapy.

#### 4. Redox regulation of cancer cell killing by cytotoxic T lymphocytes and natural killer cells

Tumors that show a dense infiltration of immune cells are regarded as “hot” while tumors containing few immune cells are regarded as “cold”. In many cancers, the hotter the tumor the better are the patient’s chances [100–102]. However, the relation between types of infiltrating immune cells are of relevance for the outcome. In the fight against cancer, cytotoxic lymphocytes (CLs) represent the most powerful soldiers in the army of the cellular immune system [103,104]. On the contrary, tumor infiltrating macrophages and myeloid derived suppressor cells (MDSCs) often represent poor prognostic markers [104]. Hence, in several cancers, including lung cancer [105], bladder cancer [106], glioblastoma [107] and renal cell carcinoma [108], a high ratio between tumor infiltrating T cells and myeloid cells prognosticates a favorable outcome [104]. The reason for the negative impact of tumor infiltrating myeloid cells is assumed to be the suppressive factors, including oxidants that are produced by myeloid cells and inhibit the cytotoxic functions of CLs. However, all myeloid cell infiltrates are not disadvantages. As discussed in more detail below certain types of macrophages may inhibit tumor growth and dendritic cells that also represent a myeloid cell type are necessary for proper tumor-specific T cell responses to evolve.

In the following section, we will summarize how the tumor redox environment affect CL-mediated killing of cancer cells. Though cytotoxic lymphocytes are sensitive to excessive levels of oxidants that trigger inactivation and apoptosis, low levels of oxidants are needed for the lymphocytes to exert their cytotoxic functions.


##### 4.1. CL-induced cytotoxicity is accompanied by oxidant production

CD8 positive cytotoxic T lymphocytes (CTLs) express T cell receptors (TCRs) and recognize tumor antigen peptides associated with MHC-I (major histocompatibility type I) cell surface proteins (Fig. 1). Thus CTL-mediated tumor cell killing is antigen-specific and requires expression of MHC-I proteins by the tumor cells. Natural killer (NK) cells, on the other hand, are more effective against cancer cells with defective expression of MHC-I molecules. Hence, recognition of tumor cells by NK cells does not require the presentation of antigens on MHC-I, but instead the NK cells interact with a wide range of activating and inhibitory receptors such as the natural cytotoxicity receptors (NCRs), killer immunoglobulin-like receptors (KIR), C-type lectin receptors and immunoglobulin like transcripts (ILT) (Fig. 1) [109]. Since NK cells express Fc receptors (recognizing the invariable Fc region of immunoglobulins) they can also bind tumor cells via tumor-bound antibodies (e.g. therapeutic antibodies such as anti-EGFR or anti-Her Ab)

Table 1

**Oxidants and antioxidants in chemotherapy.** Chemotherapeutics often utilize oxidants, which may contribute to the elimination of tumors. In other cases, oxidant formation is responsible for the side effects of the treatments.

| Tumor model/context  | In vitro or in vivo         | Finding  |
|--|-----------------------------|--|
| <b>Chemotherapeutic agents induce oxidants, alter antioxidant systems</b>  |                             |  |
| cervical cancer, 5-fluorouracil, followed by cisplatin and bleomycin   | in vivo, human              | The alterations in the circulating pro/antioxidants in advanced cervical cancer patients were investigated, before and after neoadjuvant chemotherapy. The pretreatment levels of “antioxidants” and oxidants and also the extent of their change during treatment can predict the therapeutic response to neoadjuvant chemoradiation in advanced cervix cancer [86].  |
| lung cancer, cisplatin   | in vivo, human              | Oxidative stress was detected after cisplatin based combination chemotherapy induced in NSCLC patients. The pretreatment levels of LPO and NO in NSCLC patients were significantly higher while GSH and SOD were significantly lower, compared to control. A higher elevation of oxidative stress was detected after the chemotherapy and was more evident in higher stage than lower stage patients [87].   |
| non-small cell lung cancer patients, cisplatin + etoposide   | in vivo, human              | Oxidative stress markers (LPO and NO) and antioxidant levels (GSH and SOD) were investigated in control and in NSCLC patients, before and after cisplatin + etoposide combination chemotherapy. In responders LPO and NO were low while GSH and SOD were high [88].  |
| keratinocyte apoptosis, Doxorubicin Mitochondrial superoxide   | in vitro (HaCaT)            | Doxorubicin induces keratinocyte apoptosis. Mitochondrial superoxide can mediate the apoptotic process through the oxidative modification of ERK and Bcl2 ubiquitination [98].   |
| human NSCLC (non-small cell lung cancer) cell lines, MCF-7 cells, A549 cells, MDA-MB triple negative breast cancer cells, MiaPaCa2 orthotopic xenografts | in vitro and in vivo (mice) | $\beta$ -lapachone undergo redox cycling-dependent bioactivation by NAD(P)H:quinone oxidoreductase 1 (NQO1) which is accompanied by $H_2O_2$ production. Subsequent DNA breakage and PARP1 activation depletes $NAD^+$ /ATP pools culminating in necrotic cell death. Combination of $\beta$ -lapachone with the PARP inhibitor rucaparib cause synergistic cell death by apoptosis [85].  |
| <b>Non-traditional treatments for the elimination of cancer cells that utilize oxidative stress</b>  |                             |  |
| prostate cancer, Sodium selenite   | in vitro                    | Human prostate cancer cells were treated with sodium selenite. Upon treatment, mitochondrial-dependent superoxide production was detected, that was at least partly responsible for the induction of apoptosis [89].   |
| MDR cancer cells, NO   | in vitro                    | Bifendate (DDB) nitric oxide, a synthetic nitric oxide releasing compound, effectively decreased viability of both sensitive and MDR tumor cells. The proposed mechanism includes mitochondrial tyrosine nitration and apoptosis on the one hand, and HIF1 $\alpha$ downregulation and the phosphorylation (activation) of PKB (AKT), ERK, and NF $\kappa$ B in MDR cells on the other hand [93].  |
| <b>Intervention with endogenous antioxidant systems enhance tumor killing by chemotherapeutic agents</b>   |                             |  |
| doxorubicin, selenium compounds, and D-pantethine  | in vitro and in vivo study  | Protective effect of specific agents (sodium selenite, selenomethionine, D-pantethine) during cytotoxic action of doxorubicin was demonstrated in vitro in drug-sensitive human tumor cells and in adult male Wistar rats. In contrast, was no protective effect could be detected in drug-resistant sublines [90].  |
| Glutathione transferase overexpressing cancer cells, doxorubicin derivatives   | in vitro                    | GSTs are often overexpressed and TrxR1 is often upregulated in tumors and frequently correlated to bad prognosis and resistance against a number of different anticancer drugs. These cells could be selectively targeted with drug derivatives, incorporating a sulfonamide moiety (ANS-etoposide, ANS-DOX) [92].   |
| head and neck squamous cell carcinoma, rat model of cisplatin-induced ototoxicity, cisplatin, curcumin   | in vitro, in vivo           | Cisplatin has an ototoxic side effect. The modulating effect of curcumin was investigated in the rat model of cisplatin-induced ototoxicity, and in head and neck squamous cell carcinoma cells. Curcumin attenuated all stages of tumor progression (survival, proliferation) and, by targeting pSTAT3 and Nrf2 signaling pathways, curcumin sensitized cells to cisplatin in vitro and protected from its ototoxic adverse effects in vivo [91]. |
| human leukemia cells, SOD, selective tumor killing   | in vitro                    | Certain estrogen derivatives selectively kill human leukemia cells but not normal lymphocytes. Superoxide dismutase (SOD) was identified as a target of this drug action and show that chemical modifications at the second carbon (2-OH, 2-OCH <sub>3</sub> ) of the derivatives are essential for SOD inhibition and for apoptosis induction [94].   |
| lung cancer cells, catalase, cisplatin chemotherapy  | in vitro                    | In lung cancer cells, combining Catalase (or CAT analogs) with traditional chemotherapeutic drugs, especially cisplatin, was found to be a promising therapeutic strategy. The overexpression of the antioxidant enzyme catalase (CAT) might control tumor proliferation and aggressiveness [95].  |
| A2780 and CP70 cell lines, platinum based chemotherapy APE1/Ref1 inhibitor   | in vitro                    | In patients not responding to platinum based chemotherapy, altered levels and subcellular distribution of APE1/Ref1 expression was found comparing with those who responded to platinum based chemotherapy. In A2780 and CP70 cell lines APE1/Ref1 silencing resulted in increased apoptosis after platinum based chemotherapy [96].   |
| breast cancer patients, urine samples, Doxorubicin, Cyclophosphamide chemotherapy  | in vivo, human              | Urine samples of breast cancer patients show, that there are differences in the redox homeostatic control between cancer patients. These differences may underlie predisposition to drug resistance and toxicities. There may be at least two distinct redox phenotypes with different homeostatic mechanisms balancing oxidative stress in humans [97].   |
| human head and neck cancer cells (FaDu cells)  | in vitro                    | If combined with cisplatin, 2-deoxy-glucose increases the steady-state levels of $H_2O_2$ and enhances the disruption in thiol metabolism, leading to increased oxidative stress and increased cell killing [99].  |



**Fig. 1. Tumor cell recognition by NK cells and CTLs: regulation by MΦs and MDSCs.** CD8 positive cytotoxic T lymphocytes (CTLs) express T cell receptors (TCRs) and recognize tumor antigen peptides associated with MHC-I cell surface proteins. NK cells interact with a wide range of activating and inhibitory receptors such as the natural cytotoxicity receptors (NCRs), KIR (killer immunoglobulin-like receptors), C-type lectin receptors and immunoglobulin like transcripts (ILT). Since NK cells express Fc receptors (recognizing the invariable Fc region of immunoglobulins) they can also bind tumor cells via tumor-bound antibodies (e.g. therapeutic antibodies such as anti-EGFR or anti-Her Ab). Tumor-associated macrophages and myeloid-derived suppressor cells (MDSC) exert suppressive effects on both T cells and NK cells. NOX2, eNOS and iNOS are key players in the production of superoxide, hydrogen peroxide, NO and ONOO<sup>-</sup> (The small spherical objects inside NK and T cells represent lytic granules which serve to store cytotoxic proteins.).

resulting in ADCC (antibody-dependent cell-mediated cytotoxicity) [110]. Thus, ADCC is of special importance for antibody-based cancer immunotherapies.

Although NK cells and CD8<sup>+</sup> CTL cells recognize target cells through different receptors and operate different activation pathways, their effector functions are basically identical. One of the most potent cytotoxic mechanisms of CLs (cytotoxic lymphocytes: CTLs and NK cells) is mediated by perforins [111]. In resting CLs perforin is localized to the cytotoxic granules and upon activation it is released by exocytosis. Secreted perforin undergoes calcium dependent polymerization to form cylindrical pores of 5–20 nm in the target cell membrane. According to the widely held but experimentally not fully proven view, the other powerful weapons of CLs, granzymes can enter cancer cells through these pores. Alternatively, granzymes can also enter target cells through mannose-6-phosphate receptors or via electrostatic linkage to the target cell membrane [112]. Once inside the tumor cells, the serine protease granzymes unleash apoptotic and non-apoptotic cell death pathways [113].

Both CTLs and NK cells utilize cell surface death ligands to induce programmed cell death in the target cells [114]. These death ligands include FAS-ligand, TRAIL (TNF-related apoptosis-inducing ligand), TNF $\alpha$  and they act through death receptors belonging to the TNF receptor superfamily.

Oxidants have a dual role in the regulation of CTL and NK cell function. Evans et al. [115] modelled CL-mediated cytotoxicity by treating breast cancer cells with the combination of the membrane damaging, pore forming protein streptolysin O (to mimic perforin) and granzyme B and reported oxidant production accompanying cancer cell death (Table 2). The crucial role of oxidants in cancer cell killing or

sensitization was indicated by the observation that expression of the antiapoptotic XIAP protein (which rendered tumor cells resistant to PBMC-induced ADCC) suppressed oxidation of the dye, 2',7'-dichlorodihydrofluorescein (DCFH). Oxidation of DCFH is often, although falsely, thought to be a measure of H<sub>2</sub>O<sub>2</sub> production [116]. Nevertheless, DCFH oxidation often correlates with oxidative stress.

The inhibitory effect of MnTBAP, which scavenges both O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub>, on ADCC reaction provided further support for the active role of oxidants in CL-mediated cancer cell destruction [115]. A possible mechanism underlying the sensitizing effect of oxidants to CL-mediated killing of cancer cell may be the upregulation of NK cell activating molecules on the surface of cancer cells. In multiple myeloma cells, subtoxic concentrations of melphalan or doxorubicin induced the DNA damage response (DDR) and caused cell senescence [117]. Senescent myeloma cells upregulated ligands (MICA, MICB and PVR) for NK cell activating receptors NKG2D and DNAM1 in an oxidant-dependent manner resulting in enhanced NK cell activation [118].

#### 4.2. Effects of tumor-associated inflammatory stress and therapy-induced oxidant production on CLs

The relationship between cancer and inflammation is complex [119]. It has been well established that inflammation is a common feature of most solid tumors. Chronic inflammation has a predominant role in tumor survival and proliferation, angiogenesis and immunosuppression [120]. As detailed above, cancer cells also produce H<sub>2</sub>O<sub>2</sub> and use it for proliferation signaling. Moreover, conventional cancer therapy with chemotherapeutic agents, ionizing radiation, photodynamic treatments or therapeutic antibodies are all known to induce oxidant production [62,64,68,72]. But, it is important to remember that low level production of H<sub>2</sub>O<sub>2</sub> is involved in enzyme-catalyzed redox signaling, while production of high levels of H<sub>2</sub>O<sub>2</sub> or production of hydroxyl radicals by radiation or singlet oxidation in photodynamic therapy causes indiscriminate damage. Also therapeutic antibodies, such as the anti-CD20 antibody rituximab that is used in the treatment of chronic lymphoid leukemia (CLL), triggers oxidant production by interacting with the Fc-receptor of myeloid cells [121]. The myeloid derived oxidants decrease the capacity of NK cells to exert ADCC against antibody bound tumor-cells. Treatment with NOX2-inhibitors or H<sub>2</sub>O<sub>2</sub> scavengers restored the NK cell-mediated ADCC activity in cocultures between CLL cells, NK cells and monocytes [121]. On a similar note, CTLs equipped with engineered T cell receptors (CAR-T cells = chimeric antigen receptor-redirected T cells) that co-expressed catalase were protected from hydrogen peroxide stress and maintained high tumor killing activity indicating that hydrogen peroxide contributes to T cell energy [122].

While performing their tasks, CLs are constantly exposed to oxidants and strategies to reduce the oxidative stress have been proposed to enhance the ability of CLs to kill tumor cells. However, activated CLs may partly adapt to the oxidatively stressed tumor environment by upregulating antioxidant proteins (e.g. peroxiredoxin 1 and thioredoxin 1) as demonstrated with IL-2-activated NK cells [123]. Also, DCs have been shown to provide antigen-specific T cells with antioxidative thiols during antigen presentation, which made them more resistant to oxidant-induced apoptosis [124].

The inflammatory and redox environment may differ significantly between individual tumors and between different parts of the same tumor mass. In general, macrophages and MDSCs play a central role in creating an inflammatory environment in the tumors (see below), that other tumor-infiltrating lymphocytes such as CTLs and NK cells are also exposed to and have to cope with. One of the suppressive features of macrophages and MDSCs is the production of O<sub>2</sub><sup>-</sup> and H<sub>2</sub>O<sub>2</sub> via the NADPH oxidase NOX2. The NOX2 enzyme is highly expressed in cells of the myeloid lineage, such as monocytes/macrophages and neutrophils [125]. While NOX2-derived H<sub>2</sub>O<sub>2</sub> is critical for these cells to eliminate microbes during infections, the high localized concentration of H<sub>2</sub>O<sub>2</sub>

Table 2

**Redox regulation of the antitumor functions of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells.** Oxidants may be produced and may even contribute to perforin and granzyme B-induced cancer cell killing. On the other hand, tumor-associated inflammatory stress and therapy-induced oxidant production may compromise the tumor killing effect of CLs.

| NK/CTL/LAK  | Tumor model/context   | In vitro/vivo                              | Findings   |
|---|---|--|--|
| human NK  | triple combination therapy with bortezomib, oHSV, and NK cells  | in vitro human and in vivo mouse xenograft | <ul style="list-style-type: none"> <li>• Combination treatment with bortezomib and oHSV, induced necroptotic cell death and increased the mitochondrial H<sub>2</sub>O<sub>2</sub> and JNK phosphorylation production.</li> <li>• RIPK1 and JNK inhibitors/shRNA rescued synergistic cell killing.</li> <li>• Combination treatment also significantly enhanced NK cell activation and adjuvant NK cell therapy of mice treated with bortezomib and oHSV improved antitumor efficacy [139].</li> </ul>                                 |
| human NK  | myelogenous leukemia/general cell mechanism/oxidative stress  | in vitro human                             | <ul style="list-style-type: none"> <li>• IL-2 NK and expanded NK are more resistant to H<sub>2</sub>O<sub>2</sub> than resting NK</li> <li>• PRDX1 and TXN1 are upregulated in activated NK cells</li> <li>• IL-2 confers protection on NK cells against oxidative stress mainly by up-regulation of TXN1 [123]</li> </ul>   |
| human NK  | human melanoma/NK cells   | in vitro human                             | <ul style="list-style-type: none"> <li>• During NK-mediated tumor cell killing two High Mobility Group Box-1 (HMGB1) forms are released, each displaying a specific electrophoretic mobility possibly corresponding to a different redox status.</li> <li>• In NK/melanoma cell co-cultures, NK cells specifically release an HMGB1 form that acts as chemoattractant, while dying tumor cells passively release a non-chemotactic HMGB1 [140].</li> </ul>   |
| primary NK  | MCF7 (breast cancer), A549 (lung carcinoma), MDA-MB-231 (breast adeno carcinoma), U937 (monocytic leukemia)                             | in vitro human                             | <ul style="list-style-type: none"> <li>• IR (ionizing radiation) induced an increase in expression of MICA/MICB (MHC class I-related chain molecules A and B) in MCF7 cells</li> <li>• SFN induced MICA/MICB expression in A549 and MDA-MB-231 cells and increased susceptibility to NK cell-mediated killing [141].</li> </ul>  |
| transduced T cells/NK cells                                     | Her2+ Skov3 cells and Her2-specific CAR-transduced T cells<br>K562 (Human myeloid leukemia cell line) were used as targets for NK cells | in vitro human                             | <ul style="list-style-type: none"> <li>• CAR-CAT T cells (Chimeric Antigen Receptor coexpressing catalase) protect in trans both T and NK cells from oxidative stress-mediated repression.</li> <li>• CAR-CAT T cells display an increased inhibition of intrinsic oxidant production upon T cell activation</li> <li>• CAR-CAT T cells maintain their activity under H<sub>2</sub>O<sub>2</sub> stress</li> <li>• CAR-CAT T cells mediate a protective bystander effect [122].</li> </ul>   |
| Human CD3-/CD56+ NK cells<br>CD8+ Cytotoxic T lymphocytes (CTL) | chronic lymphocytic leukemia (CLL) CD14+ monocytes<br>nanogels for cancer vaccine delivery to dendritic cells (DC)                      | in vitro human<br>in vivo human            | <ul style="list-style-type: none"> <li>• Inhibitors of oxidant formation preserved NK cell viability and restored NK cell-mediated ADCC [121].</li> <li>• Nanoparticle-triggered lysosome rupture could directly induce oxidant production in DCs, which was found to be essential for augmenting proteasome activity and downstream MHC I antigen presentation [142].</li> </ul>  |
| Cytotoxic T lymphocytes (CTL)                                   | HLA-A2+ human melanoma CTL homeostasis  | in vitro human                             | <ul style="list-style-type: none"> <li>• Superoxide production increases upon TCR (T-cell receptor) stimulation with the cognate epitope</li> <li>• Inhibition of oxidant production rescues CTL from AICD (Activation-induced cell death) without impairing their effector functions</li> <li>• Antigen-reactive primary CTL and TIL (tumor infiltrating lymphocytes) escaped AICD when treated with MnTBAP (SOD and catalase mimic) [143]</li> </ul>   |
| PBMC  | human   | in vitro human                             | <ul style="list-style-type: none"> <li>• Treatment with ox-LDL induced a significant down-regulation of proliferative response to mitogens, antigens and interleukin-2 in PBMC.</li> <li>• NK cell-mediated cytotoxic activity was significantly down-regulated by ox-LDL while treatment with N-acetylcysteine (NAC), a precursor for cysteine used in glutathione biosynthesis, induced a significant up-regulation of NK-cell activity.</li> <li>• Ox-LDL and NAC exerted opposite effects on the cytokine network [144]</li> </ul> |
| Activated PBMC  | parental IBC cell lines Inflammatory breast cancer (IBC)<br>HER2 resistance   | in vitro human                             | <ul style="list-style-type: none"> <li>• XIAP inhibit caspase activity which results in ADCC resistance</li> <li>• resistance was dependent on XIAP-mediated, caspase-independent suppression of oxidant production</li> <li>• the anti-apoptotic function-mediated by binding caspases and/or the caspase-independent oxidant-suppressive function [115]</li> </ul>   |
| mature plasma cells (PCs) in BM                                 | chemotherapeutic stress on cancer cells promote antitumor immune responses in MM (multiple myeloma) cells                               | in vitro human                             | <ul style="list-style-type: none"> <li>• Oxidant-dependent activation of the DDR (DNA damage response) pathway is involved in NKG2D and DNAM-1 genotoxic drug-induced ligand upregulation on senescent MM cells [117].</li> </ul>  |

that may be achieved via NOX2 has also been linked to immunosuppression in cancer [126–128]. Hence, in a confined inflammatory site, NOX2-derived H<sub>2</sub>O<sub>2</sub> triggers dysfunction and apoptosis of adjacent cytotoxic lymphocytes, including cytotoxic T cells and NK cells [126–129]. Genetic disruption of *Nox2* has in mouse models been shown to reduce melanoma metastasis formation by protecting tumor killing NK cells from oxidant-induced inactivation [52]. Also *Nox2*<sup>-/-</sup> mice showed a reduced growth rate of subcutaneous melanoma and lung carcinoma, but sarcoma growth and prostate cancer growth

were not affected [130,131]. Pharmacological inhibition of NOX2 by histamine dihydrochloride (HDC) is, together with low doses of IL-2, utilized as a relapse-preventive strategy for acute myeloid leukemia (AML) patients in complete remission [132,133]. The proposed mechanism of action for HDC is to protect anti-leukemic lymphocytes from oxidant-induced inactivation and thereby restoring their responsiveness to IL-2 [133].

MDSC can phenotypically be divided into granulocytic (G-MDSC) and monocytic (Mo-MDSC) subgroups. Both subgroups utilize redox



mechanism to cause T cell unresponsiveness or T cell apoptosis, and are reportedly more suppressive compared to granulocytes and monocytes from healthy subjects [134]. Granulocytic MDSC produce peroxynitrite (via combination of NOX2-derived superoxide and eNOS-derived NO) to induce T cell unresponsiveness (due to nitration-mediated T cell receptor inactivation) and T cell apoptosis [135–137]. Monocytic MDSC express iNOS, generate NO but their T cell suppressing effect doesn't appear to require peroxynitrite formation and may be due to a direct effect of NO [137,138].

## 5. Redox regulation of interactions between cancer cells and macrophages

### 5.1. Tumor associated macrophages: enemies within or potential anticancer weapons?

Macrophages (MΦ-s) are part of the innate immune system and together with monocytes and dendritic cells they comprise the mononuclear phagocyte system. While in most organs, tissue resident macrophages populate the organs prenatally, in the gut and skin circulating blood monocytes significantly contribute to the macrophage pool [145,146]. Under inflammatory conditions, however, circulating monocytes can also enter most tissue niches and differentiate to macrophages upon exposure to CSF1 (M-CSF) and GM-CSF [147].

Macrophages are also among the first host cells infiltrating the tumor mass [119]. But their role in the tumor environment is a classic case of a double-edged sword situation. On the one hand, MΦ-s have the potential to kill cancer cells. However, the presence and high number of MΦ-s in the tumor tissue is widely recognized as a negative prognostic marker. This is especially true in breast, head and neck, mesothelium, thyroid, liver, pancreas, kidney, bladder, ovarian, uterus, and cervix cancer as well as in glioma, melanoma and non-Hodgkin lymphoma while in colorectal cancer, high macrophage density was correlated with increased patient survival [148]. Thus the question arises whether macrophage-induced tumor killing is only an *in vitro* phenomenon which is not relevant in tumors or the cytotoxic activity of MΦ-s is “real” but suppressed in tumors.

Traditionally MΦ-s have been viewed as cells capable of destroying cancer cells. Macrophages activated *in vitro* with interferon gamma, LPS, glycans etc. display tumor cell killing activity. Although unlike T cells, MΦ-s are not equipped with specific antigen recognition receptors, they are still capable of binding to tumor cells (Fig. 2). To recognize cancer cells MΦ-s utilize – among other molecules - calreticulin binding receptors [149]. In damaged tumor cells (e.g. after chemotherapy), the ER protein calreticulin translocates to the plasma membrane [150] where it can bind to the MΦ-s cell surface protein CD91. Other tumor-derived DAMPs (damage-associated molecular patterns) such as ATP, HMGB1, nucleic acids also activate MΦ-s via different TLRs (HMGB1 and nucleic acids) [151] and purinoceptor P2X7R (ATP) [152]. MΦ-s can phagocytose bound tumor cells. In addition to calreticulin-CD91 interactions, cancer cell phagocytosis by macrophages is also facilitated by opsonization of cancer cells by antibodies (e.g. therapeutic antibodies such as Herceptin). ADCP (antibody-dependent cancer cell phagocytosis) leads to processing and presentation of tumor-derived antigens triggering antitumor T cell responses and thus lays the foundation for the adaptive immune response [153].

Despite possessing a wide array of potentially cytotoxic mechanisms, MΦ-s appear to be one of tumors' best friends. Recruitment of monocytes to cancer is mediated by tumor-derived chemokines (e.g. CCL2) and cytokines (CSF-1) [154]. Depending on the composition of the MΦ-s environment, MΦ-s may exist in many functional states. Although these polarization pathways most likely represent a continuous spectrum, they are often characterized by the extremes of these continuums: i.e. M1 and M2 MΦ-s [155]. IFN $\gamma$  and TNF $\alpha$  stimulate polarization towards M1 (inflammatory) MΦ-s, while IL4 and IL13 (and




Fig. 2. Recognition of tumor-associated molecular patterns by macrophages. Surface bound antibodies, externalized calreticulin or released nucleic acids or ATP can modify macrophage phenotype via interactions with specific cell surface receptors.

tumor-derived CCL2, CSF1 and IL10) initiate M2 polarization (Fig. 3) [156]. (Markers of M1 and M2 MΦ-s differ greatly between human and mouse and are summarized in [157].) M1 macrophages produce O $_2^{\cdot-}$ , H $_2$ O $_2$ , and NO and the cytotoxic cytokine TNF $\alpha$  and can thus keep tumor cells under control. However, due to exposure to IL4, IL13 and IL10, the typical phenotype of TAMs (tumor-associated macrophages) is M2, often referred to as anti-inflammatory, remodeling or “wound healing” MΦ-s. M2 cells express T cell inhibitory PD-L1 and produce T cell suppressing mediators (TGF $\beta$ , and PGE $_2$ ) [158]. Thus, the role of MΦ-s in the tumor microenvironment is to mediate immunosuppression and thus protect cancer cells from attack by cytotoxic effector cells [159]. In certain cancer types (e.g. melanoma, colorectal and gastric cancer), however, MΦ polarization is skewed towards the M1 state and infiltration of these tumors with MΦ-s is recognized as a positive prognostic marker [160–162].




Fig. 3. Macrophage polarization. Exposure of M0 macrophages to IL-4, IL-13 and IL-10 induces differentiation towards the M2 phenotype. Stimulation by LPS and IFN $\gamma$  induces M1 polarization. While M2 macrophages promote cancer cell growth, M1 macrophages are potentially cytotoxic to cancer cells.

## 5.2. Redox control mechanisms of MΦ-tumor cell interactions

The encounter of MΦ-s and cancer cells may involve antibody-dependent cellular phagocytosis/trogocytosis and consequent cytotoxicity (ADCP and ADCC, respectively). MΦ-s utilize their cell surface Fc receptors to bind tumor associated antibodies (e.g. produced by the humoral anti-tumor immune response or administered to the patient as a therapeutic antibody). This step can be followed by phagocytosis of the tumor cells (ADCP) [163] or MΦ-s biting out pieces of the tumor cells' plasma membrane (trogocytosis) [164]. The outcome of antibody-mediated MΦ responses against tumor cells can lead to tumor cell destruction (ADCC) via production of cytolytic proteases, oxidants or TNFα [165].

MΦs are prototypical  $O_2^-$ ,  $H_2O_2$ , and NO producing cells and oxidants represent one of the most potent weapons of activated MΦ-s in the combat against cancer [166,167]. While monocytes preferentially produce  $O_2^-$  and  $H_2O_2$ , MΦ-s predominantly use peroxynitrite [168] for in vitro tumor killing. Monocytes and MΦ-s operate NADPH oxidase (NOX) enzymes for superoxide production. NOX2, the dominant NOX in MΦ-s is a multisubunit protein and its components are localized in the cell membrane as well as in the cytosol. Various signals [167] can lead to NOX2 activation which requires translocation of the cytosolic subunits (p47phox, p67phox and Rac1) to the cell membrane where they associate with the membrane localized NOX2 components (gp91, p21) to form the functional holoenzyme [169]. Critical steps in the signaling cascade leading to NOX2 activation include elevated cytosolic calcium concentrations, activation of PKCα and cPLA and production of arachidonic acid with the latter inducing membrane translocation of cytosolic subunits [170].

Activated MΦs express iNOS via an NFκB-mediated pathway [171]. iNOS derived NO can combine with superoxide to form the cytotoxic product peroxynitrite (ONOO<sup>-</sup>). While NO is not considered as a cytotoxic mediator against cancer cells, rather it stimulates tumor cell proliferation, extravasation and metastasis formation, peroxynitrite on the other hand is a potent cytotoxic molecule with the potential to destroy any cells.

The question arises whether any of the MΦs antitumor effector functions are under redox control (Table 3). The early phases of MΦ-tumor cell interactions (i.e. ADCP and trogocytosis) appear to lack any significant redox control mechanism. It has been shown for example that intrasplenically injected melanoma and colon carcinoma cells are taken up rapidly by MΦs (Kupffer cells) via high affinity FcγRI and low affinity FcγRIV without any involvement of oxidants [172]. Opsonization of tumor cells by antibodies (e.g. anti-CD47) not only stimulates ADCP but it also induces a shift from M2 to M1 and results in slower tumor progression and prolonged survival of the animals [173]. Although the role of oxidants was not directly assessed in this study, the M2 to M1 shift was likely accompanied by increased oxidant producing potential of the reprogrammed MΦs. This hypothesis is supported by other studies documenting MΦ reprogramming (e.g. by gold or silver nanoparticles [174] or heme oxygenase-derived carbon monoxide and these studies demonstrated a requirement for oxidants for the shift to M1 state.

Numerous studies have addressed the role of oxidants in the tumor-killing effect of MΦs. For example pigment epithelium derived factor (PEDF) stimulated not only migration of macrophages into tumor spheroids, but phagocytosis and oxidant-mediated apoptotic killing of cancer cells [175]. Moreover, a synthetic analogue of 15-*epi*-lipotoxin A4 reprogrammed macrophages from M2 to M1 like phenotype and reprogrammed cells expressed iNOS, produced  $O_2^-$  via NADPH oxidase, and thus inhibited cancer growth [176]. Furthermore, GSH depletion caused an increased  $H_2O_2$  half-life and inhibition of tumor progression [177]. These data collectively indicate that modulations of macrophage phenotype that tip the balance between oxidants and the capacity to remove them in favor of the oxidants efficiently suppress cancer progression both in vitro and in vivo.

On the other hand, a substantial body of findings questions the role of oxidants in tumor control. Several studies suggested that NOX1/2-derived superoxide or non-specified oxidants promote M2 polarization and cancer progression [178,179].  $H_2O_2$  production by macrophages or myeloid cells has also been shown to fuel tumor progression via driving angiogenesis, promoting cancer cell proliferation, inhibition of mir328 and blocking differentiation of DCs and MΦs [180]. Radiotherapy has also been shown to stimulate invasion and metastasis formation via oxidants (and  $H_2O_2$ -induced CXCR4 expression) [181].

## 6. Therapeutic considerations

Oxidants play a multifaceted and highly complex role in tumor biology. Tremendous efforts have been made to take advantage of intratumoral redox imbalance and turn it against cancer. The controversy surrounding the role of oxidants in cancer is exemplified by the often opposite therapeutic approaches put forward by scientists. While some of these approaches stimulate oxidant production, others were based on the use of antioxidants or NOX2 inhibitors [121]. Despite some limited success, a common feature of these opposite approaches is that they all failed to provide an answer to the questions:

- Why accelerating oxidant production or using antioxidant therapies work in some instances but fail in others?
- How can we predict which type of redox-based therapy might provide therapeutic benefit?

In order to resolve these controversies surrounding redox therapies of cancer, one must first appreciate the complexity of the problem with special recognition to be given to the facts that

- Tumors cannot be viewed as a single disease as different cancer types differ greatly in the way they form, what drives their growth, invasion and metastasis and what type of redox dysregulation they display.
- Tumors cannot be viewed as a mass of highly proliferating transformed cells as the tumor stroma (including regulatory and effector immune cells) plays a fundamental role in the behavior of tumor cells and their responses to chemotherapy, immunotherapy and redox therapy.
- Oxidants are not equal and the term reactive oxygen species is inaccurate and misleading. The chemical identity of the produced oxidants, as well as compartmentalization and kinetics of oxidant production need to be given careful consideration.
- The role of oxidants should be determined individually in every tumor to decide if it is a oxidant-driven cancer or a non oxidant driven cancer.
- Immunosurveillance need to be taken into account [118]. Oxidant-induced immunosuppression of CLs promote tumor growth. The relative importance of this phenomenon relates to the content of tumor-infiltrating leukocytes and the sensitivity of the tumor cells to immune-mediated clearance.
- Molecules referred to as antioxidants do not function efficiently as scavengers of free radicals or other oxidants, but may induce anti-oxidant enzymes, or be used as a precursor of cysteine used for glutathione biosynthesis (N-acetylcysteine in particular), or have other effects on signaling that counters the effects of oxidants.

A detailed redox characterization and classification of tumors including antioxidant enzymes expression, cell signaling and transcription factor activation profiles need to be established to identify whether and how a specific type of cancer can be targeted by redox-based therapies [191]. Attempts to compile such a combinational set of predictive cellular parameters have already been made [97] and we should continue and broaden such efforts.

Table 3

**Role of oxidants and antioxidants in the regulation of MΦ-mediated cancer cell killing.** Depending on the model systems used, studies either report A) lack of effects of certain oxidants in MΦ's effector cell functions; B) demonstrate the active role of oxidants in mediating MΦ-induced cancer cell killing or C) regulate MΦ function in a way favoring cancer cell survival.

| Macrophage  | Tumor model/context   | In vitro or in vivo               | Finding  |
|---|---|-----------------------------------|--|
| <b>Lack of effect of oxidants in some MΦ effector functions</b> |   |                                   |  |
| Kupffer cells   | Mouse B16F10 melanoma cells and C26 colon carcinoma cells injected intrasplenically in mice         | in vitro/in vivo                  | <ul style="list-style-type: none"> <li>● Kupffer cells effectively arrest and phagocyte intact tumor cells after antitumor mAb treatment</li> <li>● Phagocytosis is dependent on FcγRI and FcγRIV.</li> <li>● Antibody-dependent phagocytosis is not affected by reactive oxygen or nitrogen species production [172].</li> </ul>  |
| Human PBMC-derived MΦ and murine BM-derived MΦ                  | Glioblastoma (GBM) cells, mouse xenograft model   | in vitro/in vivo                  | <ul style="list-style-type: none"> <li>● Following anti-CD47 treatment, both M1 and M2 macrophages displayed increased tumor cell phagocytosis rates in vitro (higher rates by M1).</li> <li>● Anti-CD47 treatment In vivo changed the macrophage polarization profile toward anti-tumorigenic microenvironment (increased the ratio of M1 macrophages) [173].</li> </ul>  |
| Kupffer cells   | Metastases model in Wag/Rij rats (CC531s tumor cell line injected to mesenteric vein)               | in vivo                           | <ul style="list-style-type: none"> <li>● Tumor specific monoclonal antibody prevents liver metastases from colorectal cancer.</li> <li>● Antibody-dependent phagocytosis is the main mechanism.</li> <li>● Kupffer cells are the main effector cells in eliminating tumor cells [182].</li> </ul>  |
| <b>Oxidants promote MΦ-mediated cancer cell killing</b>         |   |                                   |  |
| RAW264.7<br>BMDM  | Lung adenocarcinoma mice (Kras model), A549 xenograft models  | in vivo                           | <ul style="list-style-type: none"> <li>● Exogenous CO at low doses blocks progression of lung cancer.</li> <li>● The effects of CO are mediated by H<sub>2</sub>O<sub>2</sub>-dependent activation of MAPK/Erk1/2 - c-myc pathway as well as Notch 1-dependent negative feedback on the metabolic enzyme heme oxygenase-1 (HO-1).</li> <li>● CO treatment modulates macrophage phenotype and alters macrophage function to anti-tumoral [183].</li> </ul>  |
| tumor associated macrophages (TAMs)                             | Murine fibrosarcoma induced 3-methylcholanthrene (MCA)  | in vitro                          | <ul style="list-style-type: none"> <li>● Gold and silver nanoparticles increase the production of O<sub>2</sub>, H<sub>2</sub>O<sub>2</sub> and NO in tumor-associated macrophages.</li> <li>● High oxidant production is associated with a suppressed antioxidant enzyme system, resulting in a shift of TAMs from M2 (pro- tumorigenic) to M1 (anti-tumorigenic) nature [174].</li> </ul>  |
| WT, HIF-1α KO, and HIF-2α KO mouse MΦ                           | Mouse model of breast cancer  | in vivo model, mathematical model | <ul style="list-style-type: none"> <li>● The model and experimental data predict that tumor-associated macrophages, specifically through HIF-1α activity, can augment tumor intracellular GSH to help tumor cells develop resistance to therapy.</li> <li>● Tumors with HIF-1α deficient macrophages grow slower and have reduced levels of intracellular GSH.</li> <li>● GSH depletion can raise the rate of production of oxidants above a toxic threshold and result in inhibition of tumor growth [177].</li> </ul>  |
| RAW264.7, THP-1, BMDM   | Mouse and human tumor cell lines  | in vitro                          | <ul style="list-style-type: none"> <li>● Pigment Epithelium-Derived Factor (PEDF) stimulates the migration of macrophages towards tumor 3D spheroids and 2D cultures.</li> <li>● PEDF induces the phagocytosis of tumor cells through an indirect apoptosis-dependent mechanism.</li> <li>● PEDF increases superoxide production by macrophages.</li> <li>● Conditioned media from PEDF-treated macrophages induces apoptosis, suggesting that oxidants may be involved in tumor cells apoptosis.</li> <li>● PEDF-mediated signaling involves PNPLA2 up-regulation on macrophages to induce M1 polarization and CD47 down-regulation on tumor cells which in collaboration with ATP5B elevation on macrophages leads to phagocytosis [175].</li> </ul> |
| Human peripheral blood mononuclear cells (PBMC)                 | MV3 human melanoma cells, murine melanoma model (subcutaneous injection with B16F10 melanoma cells) | in vitro/in vivo                  | <ul style="list-style-type: none"> <li>● ATL-1, a synthetic analogue of 15-<i>epi</i>-lipoxin A4, could modulate TAM activity profile.</li> <li>● ATL-1 selectively decreased M2 surface markers in TAM, induces NO production by increasing the iNOS/arginase ratio and activated NADPH oxidase, triggering H<sub>2</sub>O<sub>2</sub> production.</li> <li>● ATL-1 inhibits tumor progression in a murine model in vivo [176].</li> </ul>  |
| Tumor-associated macrophages                                    | MCF-10A and A549 cell lines, mouse xenograft model  | in vitro/in vivo                  | <ul style="list-style-type: none"> <li>● Oncogenic MCT-1 (multiple copies in T-cell malignancy 1) activity promotes oxidant generation.</li> <li>● Overexpression of MCT-1 elevates MnSOD level via the YY1-EGFR signaling cascade, which protects cells against oxidative damage [184].</li> </ul>  |

(continued on next page)

Table 3 (continued)

| Macrophage   | Tumor model/context   | In vitro or in vivo | Finding   |
|--|---|---------------------|---|
| <b>Oxidants inhibit MΦ-mediated cancer cell killing</b>                  |   |                     |   |
| Human peripheral blood mononuclear cells (PBMC)                          | CAFs isolated from pancreatic tumor, Human pancreatic cancer cell line Panc1 and Miapaca2   | in vitro            | <ul style="list-style-type: none"> <li>● Pancreatic cancer-associated fibroblasts (CAFs) induce a tumor-promoting TAM phenotype in monocytes</li> <li>● Secreted M-CSF from CAFs led to enhanced H<sub>2</sub>O<sub>2</sub> production and M2 polarization in monocytes [185].</li> </ul>   |
| Bone marrow-derived MΦ, Resident peritoneal MΦ                           | Mouse Xenograft Models (LLC cells)  | in vivo/in vivo     | <ul style="list-style-type: none"> <li>● NOX1 and NOX2 are critical for the differentiation of monocytes to macrophages, the polarization of M2-type but not M1-type macrophages, and the occurrence of tumor-associated macrophages (TAMs).</li> <li>● Decrease in M2 macrophages and TAMs contributes to the delay in wound healing and the inhibition of tumor growth and metastasis in NOX1/2 double knockout mice [178].</li> </ul>  |
| –  | NSCLC H1299 cells, H1299 xenografts in nude mice, lung cancer tissues from patients   | in vitro/in vivo    | <ul style="list-style-type: none"> <li>● Radiotherapy can promote the invasion and metastasis of several types of cancer.</li> <li>● After irradiation, hypoxia-inducible factor 1α (HIF-1α) was increased and translocated into the nucleus and promoted the transcription of CXCR4.</li> <li>● Oxidants also play a role in the radiation-induced expression of CXCR4.</li> <li>● NAC reduce the transcriptional activation of CXCR4 promoter by 2 Gy irradiation [181].</li> </ul>                         |
| MDSCs (myeloid-derived suppressor cells)<br>Mouse peritoneal macrophages | Subcutaneous tumor models in mice: DA3 mammary carcinoma, CT26 colon carcinoma, MethA sarcoma, EL4 thymoma, Lewis lung carcinoma, MC38 colon carcinoma, C3 sarcoma.<br>Blood samples of head and neck cancer patients | in vivo             | <ul style="list-style-type: none"> <li>● Oxidant production is up-regulated in myeloid-derived suppressor cells (MDSC) in seven different tumor models and in cancer patients.</li> <li>● Increased production of O<sub>2</sub><sup>•-</sup> and H<sub>2</sub>O<sub>2</sub> in MDSCs is regulated by NADPH oxidase-2 (NOX2).</li> <li>● MDSCs from NOX2 deficient mice lost the ability to suppress T cell responses and quickly differentiated into mature macrophages and dendritic cells [126].</li> </ul> |
| Macrophages (and DCs, granulocytes)                                      | Mouse tumor models (CT-26 colon carcinoma and C3 sarcoma)   | in vitro/in vivo    | <ul style="list-style-type: none"> <li>● Differentiation of ImC (immature myeloid cells from tumor-bearing mice) was significantly delayed.</li> <li>● Rates of oxidant production were significantly higher in ImC from tumor-bearing mice. Hydrogen peroxide but not superoxide was found to be the major part of increased oxidant production.</li> <li>● ImC transferred into tumor-bearing recipients failed to differentiate into DC or macrophages [186].</li> </ul>                                   |
| ImC (immature myeloid cells)   | C3 fibrosarcoma   | in vitro (ex vivo)  | <ul style="list-style-type: none"> <li>● ImC (immature myeloid cells) generated in tumor-bearing hosts suppress the CD8<sup>+</sup> T cell response via production of oxidants.</li> <li>● Interaction of ImC with Ag-specific T cells in the presence of specific Ag-s resulted in a significant increase in oxidant production.</li> <li>● The increase in oxidant production was mediated by integrins [187].</li> </ul>   |
| murine TAMs (tumor-associated macrophages)                               | C26 murine colon carcinoma cells  | in vitro            | <ul style="list-style-type: none"> <li>● TAMs have anti-inflammatory and pro-angiogenic effects on C26 tumor cells.</li> <li>● Inhibition of NADPH oxidase in macrophages reduced the production of angiogenic proteins.</li> <li>● The stimulatory effects of TAMs on C26 cell proliferation may be related mainly to their pro-oxidant actions exerted by NADPH oxidase activity, which maintains the redox status and the angiogenic capacity of the tumor microenvironment [188].</li> </ul>              |
| Human and mouse monocytes and macrophages                                | Mouse tumor models: Urethane model, Kras model, Breast tumor model  | in vitro/in vivo    | <ul style="list-style-type: none"> <li>● O<sub>2</sub><sup>•-</sup> and H<sub>2</sub>O<sub>2</sub> production is critical for macrophage differentiation and inhibition of superoxide production specifically blocks the differentiation of M2 macrophages [179].</li> </ul>  |
| THP-1 macrophages  | Human gastrointestinal cancer cell lines, human gastric carcinoma tissue samples  | in vitro            | <ul style="list-style-type: none"> <li>● Oxidative stress by M1 and M2 macrophages induced downregulation of miR-328 and upregulation of CD44</li> <li>● CD44 is a direct target of miR-328.</li> <li>● Increased CD44 expression results in tumor progression by enhancing antioxidant defense [180].</li> </ul>   |
| Tumor-associated macrophages   | MCF-10A and A549 cell lines, mouse xenograft model  | in vitro/in vivo    | <ul style="list-style-type: none"> <li>● Oncogenic MCT-1 (multiple copies in T-cell malignancy 1) activity promotes oxidant generation.</li> <li>● Overexpression of MCT-1 elevates MnSOD level via the YY1-EGFR signaling cascade, which protects cells against oxidative damage [184].</li> </ul>   |

(continued on next page)



Table 3 (continued)

| Macrophage                                       | Tumor model/context                                    | In vitro or in vivo | Finding   |
|--|--|---------------------|---|
| Peritoneal cavity and spleen-derived macrophages | Mice inoculated with Ehrlich ascites tumor (EAT) cells | in vivo             | <ul style="list-style-type: none"> <li>● CA (caffeic acid) inhibited tumor growth and ascites volume in mice bearing Ehrlich ascites tumor (EAT).</li> <li>● CA reduced microvessel density by reducing VEGF secretion.</li> <li>● CA increases the production of proinflammatory cytokines by macrophages, increasing the tumoricidal activity</li> <li>● CA inhibits the formation of TAM macrophages and their effect on tissue remodeling [189].</li> </ul>   |
| Murine peritoneal macrophages                    | Tumor-free model, macrophage polarization              | in vitro            | <ul style="list-style-type: none"> <li>● In murine macrophages MCP-1-induced protein (MCPIP), induced by KLF4, inhibits M1 polarization by inhibiting NF-κB activation.</li> <li>● MCPIP implements M2 polarization. Induction of H<sub>2</sub>O<sub>2</sub> production, endoplasmic reticulum (ER) stress, and autophagy are required for M2 polarization.</li> <li>● MCPIP also induces C/EBPβ and PPARγ, which promote M2 polarization.</li> <li>● Inhibition of H<sub>2</sub>O<sub>2</sub> production, ER stress or autophagy inhibits IL-4-induced M2 polarization [190].</li> </ul> |

## Acknowledgements

LV is funded by the National Research, Development and Innovation Office Grants GINOP-2.3.2-15-2016-00020 TUMORDNS, GINOP-2.3.2-15-2016-00048-STAYALIVE, and OTKA K112336. CH is funded by OTKA PD116845 and Bolyai BO/00468/17/8. HJF is supported by ES023864 from the National Institutes of Health, USA. AR is supported by the Polish National Science Centre (DEC-2013/11/D/NZ2/00033) and by the Polish Ministry of Science and Higher Education [776/STYP/11/2016].

## References

- [1] G.D.a.I.I.a.P. Collaborators, Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015, *Lancet* 388 (10053) (2016) 1545–1602.
- [2] G.M.a.C.o.D. Collaborators, Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015, *Lancet* 388 (10053) (2016) 1459–1544.
- [3] E. Simeone, P.A. Ascierto, Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1, *J. Immunotoxicol.* 9 (3) (2012) 241–247.
- [4] J. Sun, S. Chia, Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly, *Br. J. Cancer* 116 (1) (2017) 4–9.
- [5] J.L. Hsu, M.C. Hung, The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer, *Cancer Metastas. Rev.* 35 (4) (2016) 575–588.
- [6] C.A. Ramos, H.E. Heslop, M.K. Brenner, CAR-T cell therapy for lymphoma, *Annu. Rev. Med.* 67 (2016) 165–183.
- [7] M. Kuroki, et al., Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity, *Anticancer Res.* 25 (6A) (2005) 3725–3732.
- [8] J.L. Meitzler, et al., NADPH oxidases: a perspective on reactive oxygen species production in tumor biology, *Antioxid. Redox Signal.* 20 (17) (2014) 2873–2889.
- [9] P. Chiarugi, From anchorage dependent proliferation to survival: lessons from redox signalling, *IUBMB Life* 60 (5) (2008) 301–307.
- [10] H.W. Lo, Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas, *Curr. Cancer Drug Targets* 10 (8) (2010) 840–848.
- [11] P. Gajate, et al., Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms, *Clin. Transl. Oncol.* (2017).
- [12] H.J. Forman, F. Ursini, M. Maiorino, An overview of mechanisms of redox signaling, *J. Mol. Cell. Cardiol.* 73 (2014) 2–9.
- [13] H.J. Forman, M. Maiorino, F. Ursini, Signaling functions of reactive oxygen species, *Biochemistry* 49 (5) (2010) 835–842.
- [14] Q. Tran, et al., Targeting cancer metabolism – revisiting the Warburg effects, *Toxicol. Res.* 32 (3) (2016) 177–193.
- [15] D.R. Spitz, et al., Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? *Ann. N. Y. Acad. Sci.* 899 (2000) 349–362.
- [16] A.L. Simons, et al., Glucose deprivation-induced metabolic oxidative stress and cancer therapy, *J. Cancer Res. Ther.* 5 (Suppl. 1) (2009) S2–S6.
- [17] T. Ozben, Oxidative stress and apoptosis: impact on cancer therapy, *J. Pharm. Sci.* 96 (9) (2007) 2181–2196.
- [18] S.I. Grivennikov, F.R. Greten, M. Karin, Immunity, inflammation, and cancer, *Cell* 140 (6) (2010) 883–899.
- [19] S. Porasuphatana, P. Tsai, G.M. Rosen, The generation of free radicals by nitric oxide synthase, *Comp. Biochem. Physiol. C Toxicol. Pharmacol.* 134 (3) (2003) 281–289.
- [20] R.M. Rapoport, F. Murad, Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP, *J. Cycl. Nucleotide Protein Phosphor Res.* 9 (4–5) (1983) 281–296.
- [21] B. Speckmann, et al., Peroxynitrite: from interception to signaling, *Arch. Biochem. Biophys.* 595 (2016) 153–160.
- [22] Y. Minami, Overview: cancer stem cell and tumor environment, *Oncology* 89 (Suppl. 1) (2015) S22–S24.
- [23] Y. Yang, et al., Reactive oxygen species in cancer biology and anticancer therapy, *Curr. Med. Chem.* 20 (30) (2013) 3677–3692.
- [24] A. Donko, et al., Dual oxidases, *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 360 (1464) (2005) 2301–2308.
- [25] R. Qi, et al., DUOX2 expression is increased in Barrett esophagus and cancerous tissues of stomach and colon, *Gastroenterol. Res. Pract.* 2016 (2016) 1835684.
- [26] A.C. Little, et al., Paradoxical roles of dual oxidases in cancer biology, *Free Radic. Biol. Med.* 110 (2017) 117–132.
- [27] A.C. Little, et al., DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties, *Oncogenesis* 5 (10) (2016) e261.
- [28] Y. Wu, et al., Dual oxidase 2 and pancreatic adenocarcinoma: IFN-gamma-mediated dual oxidase 2 overexpression results in H<sub>2</sub>O<sub>2</sub>-induced, ERK-associated up-regulation of HIF-1α and VEGF-A, *Oncotarget* 7 (42) (2016) 68412–68433.
- [29] S.M. Kim, et al., EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells, *Biochem. Biophys. Res. Commun.* 494 (3–4) (2017) 550–555.
- [30] S.W. Hong, et al., Combination treatment with erlotinib and ameplopin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway, *Lung Cancer* 106 (2017) 115–124.
- [31] J.L. Meitzler, et al., Decoding NADPH oxidase 4 expression in human tumors, *Redox Biol.* 13 (2017) 182–195.
- [32] L. Zhang, et al., New insight into the Nox4 subcellular localization in HEK293 cells: first monoclonal antibodies against Nox4, *Biochimie* 93 (3) (2011) 457–468.
- [33] K.A. Graham, et al., NADPH oxidase 4 is an oncoprotein localized to mitochondria, *Cancer Biol. Ther.* 10 (3) (2010) 223–231.
- [34] I. Takac, et al., The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4, *J. Biol. Chem.* 286 (15) (2011) 13304–13313.
- [35] K. Shanmugasundaram, et al., NOX4 functions as a mitochondrial energetic sensor coupling cancer metabolic reprogramming to drug resistance, *Nat. Commun.* 8 (1) (2017) 997.
- [36] E.C. Vaquero, et al., Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells, *J. Biol. Chem.* 279 (33) (2004) 34643–34654.
- [37] T. Mochizuki, et al., Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells, *Oncogene* 25 (26) (2006) 3699–3707.
- [38] K.P. Orcutt, et al., Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4, *Cancer Res.* 71 (11) (2011) 3932–3940.
- [39] M. Dixon, Studies on xanthine oxidase: the specificity of the system, *Biochem. J.* 20 (4) (1926) 703–718.
- [40] J. Byun, et al., 8-Nitro-2'-deoxyguanosine, a specific marker of oxidation by reactive nitrogen species, is generated by the myeloperoxidase-hydrogen peroxide-

- nitrite system of activated human phagocytes, *Biochemistry* 38 (8) (1999) 2590–2600.
- [41] H.J. Forman, et al., Protein cysteine oxidation in redox signaling: caveats on sulfenic acid detection and quantification, *Arch. Biochem. Biophys.* 617 (2017) 26–37.
- [42] G. Fujino, et al., Thioredoxin and TRAF family proteins regulate reactive oxygen species-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1, *Mol. Cell. Biol.* 27 (23) (2007) 8152–8163.
- [43] K.Z. Guyton, et al., Activation of mitogen-activated protein kinase by H<sub>2</sub>O<sub>2</sub>. Role in cell survival following oxidant injury, *J. Biol. Chem.* 271 (8) (1996) 4138–4142.
- [44] S.R. Lee, et al., Reversible inactivation of the tumor suppressor PTEN by H<sub>2</sub>O<sub>2</sub>, *J. Biol. Chem.* 277 (23) (2002) 20336–20342.
- [45] P.D. Ray, B.W. Huang, Y. Tsuji, Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling, *Cell Signal.* 24 (5) (2012) 981–990.
- [46] J. Chaudiere, R. Ferrari-Iliou, Intracellular antioxidants: from chemical to biochemical mechanisms, *Food Chem. Toxicol.* 37 (9–10) (1999) 949–962.
- [47] L.W. Oberley, Mechanism of the tumor suppressive effect of MnSOD over-expression, *Biomed. Pharmacother.* 59 (4) (2005) 143–148.
- [48] H.S. Kim, et al., SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress, *Cancer Cell* 17 (1) (2010) 41–52.
- [49] J.D. Schoenfeld, et al., O<sub>2</sub>(-) and H<sub>2</sub>O<sub>2</sub>-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate, *Cancer Cell* 32 (2) (2017) 268.
- [50] S. Kaewpila, et al., Manganese superoxide dismutase modulates hypoxia-inducible factor-1 alpha induction via superoxide, *Cancer Res.* 68 (8) (2008) 2781–2788.
- [51] H.J. Forman, K.J. Davies, F. Ursini, How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo, *Free Radic. Biol. Med.* 66 (2014) 24–35.
- [52] E. Aydin, et al., Role of NOX2-derived reactive oxygen species in NK cell-mediated control of Murine melanoma metastasis, *Cancer Immunol. Res.* 5 (9) (2017) 804–811.
- [53] M.Y. Bonner, J.L. Arbiser, The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer, *Future Med. Chem.* 6 (12) (2014) 1413–1422.
- [54] D.W. Kufe, R. P. R.R. Weichselbaum, et al. (Eds.), *Holland-Frei Cancer Medicine*, 6th edition, BC Decker, Hamilton, ON, 2003.
- [55] C. Zhu, et al., Alpha-particle radiotherapy: for large solid tumors diffusion trumps targeting, *Biomaterials* 130 (2017) 67–75.
- [56] T. Okada, et al., Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS), *J. Radiat. Res.* 51 (4) (2010) 355–364.
- [57] O. Sartor, B. M. C.R. Hauck, R.M. Macklis, Targeted use of alpha particles: current status in cancer therapeutics, *J. Nucl. Med. Radiat. Ther.* 3 (2012) 136.
- [58] D. Eriksson, T. Stigbrand, Radiation-induced cell death mechanisms, *Tumour Biol.* 31 (4) (2010) 363–372.
- [59] M.C. Support, What is Radiotherapy?, 2017. <<https://www.macmillan.org.uk>>.
- [60] L.P. Bignold, Alkylating agents and DNA polymerases, *Anticancer Res.* 26 (2B) (2006) 1327–1336.
- [61] EdCaN, Alkylating and alkylating-like agents, 2017.
- [62] Y. Tsutsumishita, et al., Involvement of H<sub>2</sub>O<sub>2</sub> production in cisplatin-induced nephrotoxicity, *Biochem. Biophys. Res. Commun.* 242 (2) (1998) 310–312.
- [63] H. Masuda, T. Tanaka, U. Takahama, Cisplatin generates superoxide anion by interaction with DNA in a cell-free system, *Biochem. Biophys. Res. Commun.* 203 (2) (1994) 1175–1180.
- [64] H.J. Shin, et al., Etoposide induced cytotoxicity mediated by ROS and ERK in human kidney proximal tubule cells, *Sci. Rep.* 6 (2016) 34064.
- [65] F. Dr, *Topoisomerase Inhibitors*. <<http://chemoth.com/types/topoisomerase>>.
- [66] E. Manchado, M. Guillamot, M. Malumbres, Killing cells by targeting mitosis, *Cell Death Differ.* 19 (3) (2012) 369–377.
- [67] E.J. Derissen, J.H. Beijnen, J.H. Schellens, Concise drug review: azacitidine and decitabine, *Oncologist* 18 (5) (2013) 619–624.
- [68] N.C. Institute, *Photodynamic Therapy for Cancer*, 2011. <<https://www.cancer.gov>>.
- [69] E.E. Kelley, et al., Increased efficacy of in vitro Photofrin photosensitization of human oral squamous cell carcinoma by iron and ascorbate, *J. Photochem. Photobiol. B* 40 (3) (1997) 273–277.
- [70] J. Luo, et al., Inactivation of primary antioxidant enzymes in mouse keratinocytes by photodynamically generated singlet oxygen, *Antioxid. Redox Signal.* 8 (7–8) (2006) 1307–1314.
- [71] H.P. Wang, et al., Phospholipid hydroperoxide glutathione peroxidase protects against singlet oxygen-induced cell damage of photodynamic therapy, *Free Radic. Biol. Med.* 30 (8) (2001) 825–835.
- [72] T. Simunek, et al., Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, *Pharmacol. Rep.* 61 (1) (2009) 154–171.
- [73] P. Menna, et al., An introduction to the metabolic determinants of anthracycline cardiotoxicity, *Cardiovasc. Toxicol.* 7 (2) (2007) 80–85.
- [74] J.H. Doroshov, K.J. Davies, Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical, *J. Biol. Chem.* 261 (7) (1986) 3068–3074.
- [75] D.G. Deavall, et al., Drug-induced oxidative stress and toxicity, *J. Toxicol.* 2012 (2012) 645460.
- [76] R. Jeelani, et al., Cyclophosphamide and acrolein induced oxidative stress leading to deterioration of metaphase II mouse oocyte quality, *Free Radic. Biol. Med.* 110 (2017) 11–18.
- [77] D. Siegel, C. Yan, D. Ross, NAD(P)H: quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones, *Biochem. Pharmacol.* 83 (8) (2012) 1033–1040.
- [78] L. Virag, C. Szabo, The therapeutic potential of poly(ADP-ribose) polymerase inhibitors, *Pharmacol. Rev.* 54 (3) (2002) 375–429.
- [79] L. Virag, et al., Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly (ADP-ribose) synthetase (PARS) activation, *Immunology* 94 (3) (1998) 345–355.
- [80] L. Virag, A.L. Salzman, C. Szabo, Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death, *J. Immunol.* 161 (7) (1998) 3753–3759.
- [81] C. Hegedűs, L. Virag, Inputs and outputs of poly(ADP-ribosyl)lation: relevance to oxidative stress, *Redox Biol.* 2 (2014) 978–982.
- [82] L. Virag, et al., Poly(ADP-ribose) signaling in cell death, *Mol. Asp. Med.* 34 (6) (2013) 1153–1167.
- [83] X. Huang, et al., An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis, *Cancer Res.* 72 (12) (2012) 3038–3047.
- [84] L.S. Li, et al., NQO1-mediated tumor-selective lethality and radiosensitization for head and neck cancer, *Mol. Cancer Ther.* 15 (7) (2016) 1757–1767.
- [85] X. Huang, et al., Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly(ADP-ribose) polymerase inhibitors, *Cancer Cell* 30 (6) (2016) 940–952.
- [86] A. Sharma, et al., Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response, *Mol. Cell. Biochem.* 341 (1–2) (2010) 65–72.
- [87] A.N. Srivastava, et al., Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients, *Asian Pac. J. Cancer Prev.* 11 (2) (2010) 465–471.
- [88] A. Gupta, et al., Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response, *Respirology* 15 (2) (2010) 349–356.
- [89] N. Xiang, R. Zhao, W. Zhong, Sodium selenite induces apoptosis by generation of superoxide via the mitochondrial-dependent pathway in human prostate cancer cells, *Cancer Chemother. Pharmacol.* 63 (2) (2009) 351–362.
- [90] R. Panchuk, et al., Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: in vitro and in vivo study, *Croat. Med. J.* 55 (3) (2014) 206–217.
- [91] A.R. Feroni, et al., Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling, *Br. J. Cancer* 113 (10) (2015) 1434–1444.
- [92] M.W. van Gisbergen, et al., Chemical reactivity window determines prodrug efficiency toward glutathione transferase overexpressing cancer cells, *Mol. Pharm.* 13 (6) (2016) 2010–2025.
- [93] Z. Ren, et al., Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells, *J. Cell. Mol. Med.* 20 (6) (2016) 1095–1105.
- [94] P. Huang, et al., Superoxide dismutase as a target for the selective killing of cancer cells, *Nature* 407 (6802) (2000) 390–395.
- [95] V.A. de Oliveira, et al., In vitro evaluation of antitumoral efficacy of catalase in combination with traditional chemotherapeutic drugs against human lung adenocarcinoma cells, *Tumour Biol.* 37 (8) (2016) 10775–10784.
- [96] Y. Zhang, et al., Alterations in the expression of the apurinic/aprimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and identification of the therapeutic potential of APE1/Ref-1 inhibitor, *Int. J. Oncol.* 35 (5) (2009) 1069–1079.
- [97] D. Ilyasova, et al., Individual responses to chemotherapy-induced oxidative stress, *Breast Cancer Res. Treat.* 125 (2) (2011) 583–589.
- [98] S. Luanpitpong, et al., Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination, *Biochem. Pharmacol.* 83 (12) (2012) 1643–1654.
- [99] A.L. Simons, et al., 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells, *Cancer Res.* 67 (7) (2007) 3364–3370.
- [100] L.L. van der Woude, et al., Migrating into the tumor: a roadmap for T cells, *Trends Cancer* 3 (11) (2017) 797–808.
- [101] S. Spranger, Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment, *Int. Immunol.* 28 (8) (2016) 383–391.
- [102] G. Rahir, M. Moser, Tumor microenvironment and lymphocyte infiltration, *Cancer Immunol. Immunother.* 61 (6) (2012) 751–759.
- [103] C. Fortes, et al., Tumor-infiltrating lymphocytes predict cutaneous melanoma survival, *Melanoma Res.* 25 (4) (2015) 306–311.
- [104] M.D. Iglesia, et al., Genomic analysis of immune cell infiltrates across 11 tumor types, *J. Natl. Cancer Inst.* 108 (2016) 11.
- [105] L. Jiang, et al., Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer, *Immunol. Res.* 62 (3) (2015) 316–324.
- [106] M.F. Chevalier, et al., ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence, *J. Clin. Invest.* 127 (8) (2017) 2916–2929.
- [107] S. Han, et al., Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma, *BMC Cancer* 15 (2015) 617.
- [108] F. Donskov, et al., Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial, *Br. J. Cancer* 94 (2) (2006) 218–226.
- [109] L. Chavez-Galan, et al., Cell death mechanisms induced by cytotoxic lymphocytes, *Cell. Mol. Immunol.* 6 (1) (2009) 15–25.

- [110] D.E. Oppenheim, et al., Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy, *Br. J. Cancer* 110 (5) (2014) 1221–1227.
- [111] F. Zhou, Perforin: more than just a pore-forming protein, *Int. Rev. Immunol.* 29 (1) (2010) 56–76.
- [112] S.K. Nadimpalli, P.K. Amancha, Evolution of mannose 6-phosphate receptors (MPR300 and 46): lysosomal enzyme sorting proteins, *Curr. Protein Pept. Sci.* 11 (1) (2010) 68–90.
- [113] S. Hoves, J.A. Trapani, I. Voskoboinik, The battlefield of perforin/granzyme cell death pathways, *J. Leukoc. Biol.* 87 (2) (2010) 237–243.
- [114] Y. Kojima, et al., Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity, *Biochem. Biophys. Res. Commun.* 296 (2) (2002) 328–336.
- [115] M.K. Evans, et al., X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity, *Cell Death Dis.* 7 (2016) e2073.
- [116] B. Kalyanaraman, et al., Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations, *Free Radic. Biol. Med.* 52 (1) (2012) 1–6.
- [117] A. Soriani, et al., Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1, *J. Immunol.* 193 (2) (2014) 950–960.
- [118] A. Sagiv, et al., NKG2D ligands mediate immunosurveillance of senescent cells, *Aging* 8 (2) (2016) 328–344.
- [119] L.L. Munn, *Cancer and inflammation*, Wiley Interdiscip. Rev. Syst. Biol. Med. 9 (2017) 2.
- [120] K. Nakamura, M.J. Smyth, Targeting cancer-related inflammation in the era of immunotherapy, *Immunol. Cell Biol.* 95 (4) (2017) 325–332.
- [121] O. Werlenius, et al., Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells, *Oncotarget* 7 (22) (2016) 32046–32053.
- [122] M.A. Ligtenberg, et al., Coexpressed catalase protects chimeric antigen receptor-redirection T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity, *J. Immunol.* 196 (2) (2016) 759–766.
- [123] K. Mimura, et al., Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress, *Cancer Immunol. Immunother.* 66 (5) (2017) 605–613.
- [124] A. Martner, et al., Redox remodeling by dendritic cells protects antigen-specific T cells against oxidative stress, *J. Immunol.* 187 (12) (2011) 6243–6248.
- [125] K. Bedard, K.H. Krause, The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology, *Physiol. Rev.* 87 (1) (2007) 245–313.
- [126] C.A. Corzo, et al., Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells, *J. Immunol.* 182 (9) (2009) 5693–5701.
- [127] J. Aurelius, et al., NOX2-dependent immunosuppression in chronic myelomonocytic leukemia, *J. Leukoc. Biol.* 102 (2) (2017) 459–466.
- [128] J. Aurelius, et al., Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis, *Blood* 119 (24) (2012) 5832–5837.
- [129] K. Hellstrand, et al., Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites, *J. Immunol.* 153 (11) (1994) 4940–4947.
- [130] T. Kelkka, et al., Mice lacking NCF1 exhibit reduced growth of implanted melanoma and carcinoma tumors, *PLoS One* 8 (12) (2013) e84148.
- [131] M.A. Ligtenberg, et al., Methylcholanthrene-induced sarcomas develop independently from NOX2-derived ROS, *PLoS One* 10 (6) (2015) e0129786.
- [132] M. Brune, et al., Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial, *Blood* 108 (1) (2006) 88–96.
- [133] A. Martner, et al., Immunotherapeutic strategies for relapse control in acute myeloid leukemia, *Blood Rev.* 27 (5) (2013) 209–216.
- [134] V. Bronte, et al., Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards, *Nat. Commun.* 7 (2016) 12150.
- [135] S. Nagaraj, et al., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer, *Nat. Med.* 13 (7) (2007) 828–835.
- [136] S. Ostrand-Rosenberg, Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity, *Cancer Immunol. Immunother.* 59 (10) (2010) 1593–1600.
- [137] P.L. Raber, et al., Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways, *Int. J. Cancer* 134 (12) (2014) 2853–2864.
- [138] A. Kotsakis, et al., Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples, *J. Immunol. Methods* 381 (1–2) (2012) 14–22.
- [139] J.Y. Yoo, et al., Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy, *Clin. Cancer Res.* 22 (21) (2016) 5265–5276.
- [140] M. Parodi, et al., Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment, *Oncoimmunology* 4 (12) (2015) e1052353.
- [141] P.J. Amin, B.S. Shankar, Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis, *Life Sci.* 126 (2015) 19–27.
- [142] C. Wang, et al., Self-adjuvanted nanovaccine for cancer immunotherapy: role of lysosomal rupture-induced ROS in MHC class I antigen presentation, *Biomaterials* 79 (2016) 88–100.
- [143] H. Norell, et al., Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27–35)-reactive T cells from activation-induced cell death, *Cancer Res.* 69 (15) (2009) 6282–6289.
- [144] M. Viora, et al., Redox imbalance and immune functions: opposite effects of oxidized low-density lipoproteins and N-acetylcysteine, *Immunology* 104 (4) (2001) 431–438.
- [145] F. Ginhoux, S. Jung, Monocytes and macrophages: developmental pathways and tissue homeostasis, *Nat. Rev. Immunol.* 14 (6) (2014) 392–404.
- [146] S. Epelman, K.J. Lavine, G.J. Randolph, Origin and functions of tissue macrophages, *Immunity* 41 (1) (2014) 21–35.
- [147] P.B. Fisher, *Mechanisms of Differentiation II* CRC Press, 1990, p. 216.
- [148] N. Gul, M. van Egmond, Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer, *Cancer Res.* 75 (23) (2015) 5008–5013.
- [149] M. Feng, et al., Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk, *Proc. Natl. Acad. Sci. USA* 112 (7) (2015) 2145–2150.
- [150] N. Chapat, et al., Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference, *J. Mol. Med.* 85 (10) (2007) 1069–1076.
- [151] N. Jounai, et al., Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination, *Front. Cell. Infect. Microbiol.* 2 (2012) 168.
- [152] R. Coutinho-Silva, P.M. Persechini, P2Z purinoceptor-associated pores induced by extracellular ATP in macrophages and J774 cells, *Am. J. Physiol.* 273 (6 Pt 1) (1997) C1793–C1800.
- [153] M. Watanabe, et al., Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210, *Breast Cancer Res. Treat.* 53 (3) (1999) 199–207.
- [154] R.Z. Panni, D.C. Linehan, D.G. DeNardo, Targeting tumor-infiltrating macrophages to combat cancer, *Immunotherapy* 5 (10) (2013) 1075–1087.
- [155] S. Arora, et al., Macrophages: their role, activation and polarization in pulmonary diseases, *Immunobiology* (2017).
- [156] F.O. Martinez, S. Gordon, The M1 and M2 paradigm of macrophage activation: time for reassessment, *F1000Prime Rep.* 6 (2014) 13.
- [157] F.O. Martinez, et al., Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences, *Blood* 121 (9) (2013) e57–e69.
- [158] S.R. Woo, L. Corrales, T.F. Gajewski, Innate immune recognition of cancer, *Annu. Rev. Immunol.* 33 (2015) 445–474.
- [159] S.A. Eccles, P. Alexander, Macrophage content of tumours in relation to metastatic spread and host immune reaction, *Nature* 250 (5468) (1974) 667–669.
- [160] F. Piras, et al., The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase, *Cancer* 104 (6) (2005) 1246–1254.
- [161] M. Erreni, A. Mantovani, P. Allavena, Tumor-associated macrophages (TAM) and inflammation in colorectal cancer, *Cancer Microenviron.* 4 (2) (2011) 141–154.
- [162] Y. Funada, et al., Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer, *Oncol. Rep.* 10 (2) (2003) 309–313.
- [163] E. Oflazoglu, et al., Macrophages and Fc-receptor interactions contribute to the antitumor activities of the anti-CD40 antibody SGN-40, *Br. J. Cancer* 100 (1) (2009) 113–117.
- [164] R. Velmurugan, et al., Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells, *Mol. Cancer Ther.* 15 (8) (2016) 1879–1889.
- [165] K. Weiskopf, I.L. Weissman, Macrophages are critical effectors of antibody therapies for cancer, *MAbs* 7 (2) (2015) 303–310.
- [166] M.S. Cohen, J.L. Ryan, R.K. Root, The oxidative metabolism of thioglycollate-elicited mouse peritoneal macrophages: the relationship between oxygen, superoxide and hydrogen peroxide and the effect of monolayer formation, *J. Immunol.* 127 (3) (1981) 1007–1011.
- [167] C.Y. Lin, et al., Lipopolysaccharide-induced nitric oxide, prostaglandin E2, and cytokine production of mouse and human macrophages are suppressed by phyto-phytin-b, *Int. J. Mol. Sci.* 18 (2017) 12.
- [168] J.H. Martin, S.W. Edwards, Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas Reactive nitrogen intermediates are employed by macrophages in tumor cell killing, *J. Immunol.* 150 (8 Pt 1) (1993) 3478–3486.
- [169] W.M. Nauseef, Assembly of the phagocyte NADPH oxidase, *Histochem. Cell Biol.* 122 (4) (2004) 277–291.
- [170] M.K. Cathcart, Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis, *Arterioscler. Thromb. Vasc. Biol.* 24 (1) (2004) 23–28.
- [171] M. Brodsky, et al., The anti-inflammatory effects of the tellurium redox modulating compound, AS101, are associated with regulation of NFκB signaling pathway and nitric oxide induction in macrophages, *J. Inflamm.* 7 (1) (2010) 3.
- [172] N. Gul, et al., Macrophages eliminate circulating tumor cells after monoclonal antibody therapy, *J. Clin. Invest.* 124 (2) (2014) 812–823.
- [173] M. Zhang, et al., Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo, *PLoS One* 11 (4) (2016) e0153550.
- [174] R. Pal, et al., Noble metal nanoparticle-induced oxidative stress modulates tumor associated macrophages (TAMs) from an M2 to M1 phenotype: an in vitro approach, *Int. Immunopharmacol.* 38 (2016) 332–341.
- [175] D. Martinez-Marin, et al., PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro, *PLoS One* 12 (4) (2017) e0174968.
- [176] R.L. Simoes, et al., Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression, *Int. J. Cancer* 140 (2) (2017) 346–357.
- [177] D. Chen, et al., Involvement of tumor macrophage HIFs in chemotherapy

- effectiveness: mathematical modeling of oxygen, pH, and glutathione, *PLoS One* 9 (10) (2014) e107511.
- [178] Q. Xu, et al., NADPH oxidases are essential for macrophage differentiation, *J. Biol. Chem.* 291 (38) (2016) 20030–20041.
- [179] Y. Zhang, et al., ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages, *Cell Res.* 23 (7) (2013) 898–914.
- [180] T. Ishimoto, et al., Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation, *Carcinogenesis* 35 (5) (2014) 1003–1011.
- [181] Q. Gu, et al., Hypoxia-inducible factor 1alpha (HIF-1alpha) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1alpha/CXCR4 pathway in non-small cell lung carcinoma cells, *Oncotarget* 6 (13) (2015) 10893–10907.
- [182] G.J. van der Bij, et al., Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy, *J. Hepatol.* 53 (4) (2010) 677–685.
- [183] Z. Nemeth, et al., Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth, *Oncotarget* 7 (17) (2016) 23919–23932.
- [184] H.Y. Tseng, et al., Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression, *Oncogenesis* 6 (4) (2017) e313.
- [185] A. Zhang, et al., Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma, *Cancer Med.* 6 (2) (2017) 463–470.
- [186] S. Kusmartsev, D.I. Gabrilovich, Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species, *J. Leukoc. Biol.* 74 (2) (2003) 186–196.
- [187] S. Kusmartsev, et al., Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species, *J. Immunol.* 172 (2) (2004) 989–999.
- [188] L. Luput, et al., Tumor-associated macrophages favor C26 murine colon carcinoma cell proliferation in an oxidative stress-dependent manner, *Oncol. Rep.* 37 (4) (2017) 2472–2480.
- [189] N. Orsolich, et al., Oxidative stress, polarization of macrophages and tumour angiogenesis: efficacy of caffeic acid, *Chem. Biol. Interact.* 256 (2016) 111–124.
- [190] N. Kapoor, et al., Transcription factors STAT6 and KLF4 implement macrophage polarization via the dual catalytic powers of MCP1P, *J. Immunol.* 194 (12) (2015) 6011–6023.
- [191] J. Wang, J. Yi, Cancer cell killing via ROS: to increase or decrease, that is the question, *Cancer Biol. Ther.* 7 (12) (2008) 1875–1884.